WO2013084943A1 - Catheter assembly - Google Patents

Catheter assembly Download PDF

Info

Publication number
WO2013084943A1
WO2013084943A1 PCT/JP2012/081513 JP2012081513W WO2013084943A1 WO 2013084943 A1 WO2013084943 A1 WO 2013084943A1 JP 2012081513 W JP2012081513 W JP 2012081513W WO 2013084943 A1 WO2013084943 A1 WO 2013084943A1
Authority
WO
WIPO (PCT)
Prior art keywords
catheter assembly
shaft
seal mechanism
catheter
sheath
Prior art date
Application number
PCT/JP2012/081513
Other languages
French (fr)
Japanese (ja)
Inventor
本間康之
中川雄司
畑優
Original Assignee
テルモ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テルモ株式会社 filed Critical テルモ株式会社
Publication of WO2013084943A1 publication Critical patent/WO2013084943A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/34Trocars; Puncturing needles
    • A61B17/3415Trocars; Puncturing needles for introducing tubes or catheters, e.g. gastrostomy tubes, drain catheters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/46Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor
    • A61F2/4603Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor for insertion or extraction of endoprosthetic joints or of accessories thereof
    • A61F2/4618Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor for insertion or extraction of endoprosthetic joints or of accessories thereof of cartilage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00969Surgical instruments, devices or methods, e.g. tourniquets used for transplantation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/34Trocars; Puncturing needles
    • A61B17/3417Details of tips or shafts, e.g. grooves, expandable, bendable; Multiple coaxial sliding cannulas, e.g. for dilating
    • A61B2017/3419Sealing means between cannula and body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/46Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor
    • A61F2/4603Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor for insertion or extraction of endoprosthetic joints or of accessories thereof
    • A61F2002/4625Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor for insertion or extraction of endoprosthetic joints or of accessories thereof with relative movement between parts of the instrument during use
    • A61F2002/4627Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor for insertion or extraction of endoprosthetic joints or of accessories thereof with relative movement between parts of the instrument during use with linear motion along or rotating motion about the instrument axis or the implantation direction, e.g. telescopic, along a guiding rod, screwing inside the instrument
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/46Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor
    • A61F2/4603Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor for insertion or extraction of endoprosthetic joints or of accessories thereof
    • A61F2002/4625Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor for insertion or extraction of endoprosthetic joints or of accessories thereof with relative movement between parts of the instrument during use
    • A61F2002/4628Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor for insertion or extraction of endoprosthetic joints or of accessories thereof with relative movement between parts of the instrument during use with linear motion along or rotating motion about an axis transverse to the instrument axis or to the implantation direction, e.g. clamping

Definitions

  • the present invention relates to a catheter assembly including an isolation mechanism for isolating a treatment target site and other tissues in a living body.
  • One method of regenerative treatment of cartilage damage sites is a method of transplanting cultured cells and bone marrow-derived cells prepared by concentrating collected bone marrow fluid under arthroscopy.
  • cartilage damage sites cartilage defects
  • Clinical Orthopedic Surgery Ichiro Sekiya, Vol. 45, No. 9, Medical School, September 25, 2010, p. 791-795
  • Synovial cells collected from patients are cultured for 2 weeks, and the cartilage damage site is dissected (shaved) under arthroscopy, and then 0.1 mL of cell suspension is injected into the cartilage damage site using a needle and syringe. To do.
  • An object of the present invention is to provide a catheter assembly capable of preventing liquid from flowing into a target site.
  • a catheter assembly includes a hollow shaft having a lumen, a seal mechanism provided on the outer periphery in the vicinity of the tip of the shaft and capable of contraction and expansion, and the shaft. And a sheath that can accommodate the contracted seal mechanism, and when the expanded seal mechanism is pressed around the treatment target site in a living body, The outside is separated from the outside by the sealing mechanism.
  • the treatment target region is expanded from other tissues by expanding the seal mechanism in the living body by a simple operation from outside the living body, and pressing the expanded seal mechanism around the treatment target region. It isolates and can prevent the inflow of the liquid to a treatment object site
  • the sealing mechanism may include an isolation film joined to an outer periphery of the shaft and a frame that supports the isolation film. According to this configuration, it is possible to improve the adhesion of the seal mechanism to the periphery of the treatment target site, and it is possible to more suitably prevent liquid from entering from the outside to the inside of the treatment target site.
  • the frame is a ring-shaped flexible member provided on an outer peripheral edge of the isolation membrane, and the seal mechanism is configured so that when it comes out of the sheath, the frame It is good to be a structure which self-expands by elastic restoring force. According to this configuration, the seal mechanism can be expanded by a single operation without requiring a separate expansion operation, and the operability is excellent.
  • a plurality of the frames may be provided around the shaft, and may be configured to expand radially when the seal mechanism is expanded. According to this configuration, the rigidity of the entire seal mechanism at the time of expansion can be increased, and the adhesion between the seal mechanism and the periphery of the treatment target site can be effectively increased.
  • the sealing mechanism may include a connecting member that is connected to the plurality of frames and that is displaceable along the shaft on the proximal end side of the shaft with respect to the isolation film.
  • the adhesion between the sealing mechanism and the periphery of the treatment target site can be suitably increased.
  • the sheath has a bent portion in the longitudinal direction, and the pressing device has flexibility to bend along the sheath, for example, a knee joint in arthroscopic surgery
  • a treatment in which the treatment target site is in a direction bent with respect to the insertion direction of the catheter assembly can be suitably performed.
  • the cell suspension can be injected without loss.
  • the seal mechanism when the seal mechanism has an annular seal member or a porous body on the side in contact with the treatment target site, the sealing performance between the seal mechanism and the treatment target site is improved, and the treatment is performed. It is possible to more reliably prevent the liquid from flowing into the target site.
  • the shaft has an imaging lumen into which the imaging means can be inserted and an illumination lumen into which the light irradiation means can be inserted, so that the catheter can be used even when an endoscope or an arthroscope is not used.
  • the assembly can be reliably placed at the treatment target site.
  • the state of the damaged site can be directly observed, and after confirming that the liquid has been completely removed, cells can be injected, and treatment can be performed reliably.
  • the treatment target site can be isolated from other tissues by a simple operation from outside the living body with respect to the treatment target site, thereby allowing the liquid to flow into the treatment target site. Can be prevented.
  • FIG. 1 is a partially omitted perspective view of a catheter assembly according to a first embodiment of the present invention.
  • 2A is a partially omitted vertical cross-sectional view of the sealing mechanism of the catheter assembly shown in FIG. 1 in a contracted state
  • FIG. 2B is a diagram of an expanded state of the sealing mechanism of the catheter assembly shown in FIG. FIG. It is a perspective view of the expanded sealing mechanism.
  • FIG. 4A is a first diagram illustrating a method of using the catheter assembly according to the first embodiment
  • FIG. 4B is a second diagram illustrating a method of using the catheter assembly according to the first embodiment.
  • FIG. 4C is a third diagram illustrating a method of using the catheter assembly according to the first embodiment
  • FIG. 4D is a fourth diagram illustrating a method of using the catheter assembly according to the first embodiment.
  • FIG. FIG. 5A is a fifth diagram illustrating a method of using the catheter assembly according to the first embodiment
  • FIG. 5B is a sixth diagram illustrating a method of using the catheter assembly according to the first embodiment.
  • FIG. 5C is a seventh diagram illustrating a method of using the catheter assembly according to the first embodiment. It is a partially-omission perspective view of the catheter assembly which concerns on 2nd Embodiment of this invention.
  • FIG. 7A is a longitudinal sectional view in a contracted state of the sealing mechanism of the catheter assembly according to the second embodiment
  • FIG. 7B is a longitudinal sectional view in an expanded state of the sealing mechanism of the catheter assembly according to the second embodiment.
  • FIG. 7A is a longitudinal sectional view in a contracted state of the sealing mechanism of the catheter assembly according to the second embodiment
  • FIG. 7B is a longitudinal sectional view in an expanded state of the sealing mechanism of the catheter assembly according to
  • FIG. 9A is a first diagram illustrating a method for using the catheter assembly according to the second embodiment
  • FIG. 9B is a second diagram illustrating a method for using the catheter assembly according to the second embodiment
  • FIG. 9C is a third diagram illustrating a method of using the catheter assembly according to the second embodiment
  • FIG. 9D is a fourth diagram illustrating a method of using the catheter assembly according to the second embodiment.
  • FIG. 10A is a fifth diagram for explaining how to use the catheter assembly according to the second embodiment
  • FIG. 10B is a sixth diagram for explaining how to use the catheter assembly according to the second embodiment.
  • FIG. 10C is a seventh diagram illustrating a method for using the catheter assembly according to the second embodiment
  • FIG. 10D is an eighth diagram illustrating a method for using the catheter assembly according to the second embodiment.
  • FIG. FIG. 11A is a longitudinal sectional view of a distal end portion of a catheter assembly provided with a seal mechanism according to a modification
  • FIG. 11B is a longitudinal sectional view of a distal end portion of the catheter assembly provided with a shaft according to the modification. .
  • FIG. 1 is a partially omitted perspective view of a catheter assembly 10 according to a first embodiment of the present invention.
  • the catheter assembly 10 includes a catheter 12, a contractible and expandable seal mechanism 14 provided near the distal end of the catheter 12, and a sheath 16 through which the catheter 12 and the seal mechanism 14 can be inserted.
  • the expanded seal mechanism 14 is pressed against the periphery of the treatment target site to isolate the inside of the treatment target site from other sites.
  • FIG. 1 shows a state in which the seal mechanism 14 is accommodated in the sheath 16.
  • FIG. 2A is a partially omitted longitudinal sectional view of the catheter assembly 10 with the sealing mechanism 14 contracted
  • FIG. 2B is a partially omitted longitudinal section of the catheter assembly 10 with the sealing mechanism 14 expanded
  • FIG. FIG. 3 is a perspective view of the seal mechanism 14 in the expanded state.
  • the catheter 12 includes a hollow shaft 18 constituting the main body of the catheter 12 and a hollow hub 20 connected to the proximal end portion of the shaft 18.
  • the shaft 18 is a flexible tubular member, and a lumen 18a is formed to penetrate in the axial direction.
  • the dimension of the shaft 18 is appropriately selected according to the living body in which the shaft 18 is used and the size of the treatment target site.
  • the outer diameter is selected. Is preferably set to about 1 to 10 mm, the inner diameter is set to about 0.5 to 9.5 mm, and the total length is set to about 20 to 300 mm.
  • the hub 20 connected to the base end portion of the shaft 18 has a hub lumen 20a communicating with the lumen 18a of the shaft 18 penetrating in the axial direction.
  • the hub 20 is configured to be connectable to a suction device that generates a negative pressure for liquid suction and an injection tool for supplying a cell suspension to the catheter 12.
  • the suction device is, for example, a mechanism including a vacuum pump and a collection container, an aspirator, a syringe, or the like.
  • the injection tool is, for example, a syringe filled with a cell suspension.
  • the shaft 18 and the hub 20 constituting the catheter 12 are made of various materials such as ethylene-tetrafluoroethylene copolymer (ETFE), polyether nylon, polyamide, polyester, polyurethane, polyethylene, polypropylene, and polyvinyl chloride.
  • ETFE ethylene-tetrafluoroethylene copolymer
  • polyether nylon polyether nylon
  • polyamide polyamide
  • polyester polyurethane
  • polyethylene polypropylene
  • polyvinyl chloride polyvinyl chloride
  • the seal mechanism 14 includes an isolation film 22 whose inner periphery is joined to the outer periphery of the shaft 18 and a frame 24 that supports the isolation film 22, and in a expanded state, a treatment target site (for example, The site to be treated is sealed by being pressed against the cartilage injury site.
  • the isolation film 22 is a sheet-like member having flexibility such that it can be easily folded into a size that can be accommodated in the sheath 16.
  • the shaft 18 of the catheter 12 passes through a hole provided in the central portion of the isolation film 22, and the distal end portion of the shaft 18 protrudes from the isolation film 22 when the isolation film 22 is expanded.
  • the size of the isolation membrane 22 is appropriately selected according to the living body in which the isolation membrane 22 is used and the size of the treatment target site, and in particular, when used for arthroscopic surgery at the knee joint,
  • the diameter is preferably set to about 1.5 to 40 mm.
  • the isolation film 22 is made of a material capable of sealing the treatment target site, and includes, for example, vinyl chloride, polyurethane elastomer, styrene-ethylene-butylene-styrene copolymer (SEBS), styrene-ethylene-propylene-styrene copolymer. It is preferable to use a thermoplastic elastomer such as (SEPS), a thermoplastic resin such as nylon or PET, or a thermosetting resin such as rubber or silicone elastomer. Moreover, it is also possible to use these in combination as appropriate.
  • the isolation film 22 is transparent so that a state in which the liquid in the treatment target region is sucked and a state in which cells are injected can be visually confirmed with an endoscope or an arthroscope while the treatment target region is covered by the seal mechanism 14.
  • the frame 24 is provided on the outer peripheral edge portion of the isolation film 22, supports the isolation film 22, and is a ring-shaped member having flexibility. Since the seal mechanism 14 includes a flexible frame 24, the seal mechanism 14 can be inserted into the sheath 16 together with the shaft 18 by contracting due to elastic deformation of the frame 24, as shown in FIG. As shown in FIG. 2B, when the sheath 16 comes out from the distal end, it can be expanded by the elastic restoring force of the frame 24.
  • Such a frame 24 is only required to have elasticity that can be elastically deformed and to be elastically recoverable in shape, for example, a metal having elasticity or superelasticity such as stainless steel, tantalum, cobalt alloy, titanium alloy or the like. It is made of a material or various polymers such as polyolefin such as polyethylene, polypropylene and ethylene-vinyl acetate copolymer, polyvinyl chloride, polymethyl methacrylate, polycarbonate, polybutadiene, polyamide and polyester.
  • the constituent material of the frame 24 is a superelastic alloy (shape memory alloy) such as a titanium alloy because the seal mechanism 14 can be reliably expanded when it comes out of the sheath 16.
  • the sheath 16 is a tubular member having a lumen 16b into which the catheter 12 and the contracted seal mechanism 14 can be inserted, and both ends are open.
  • the sheath 16 is bent downward in the vicinity of the distal end portion, and the distal end opening 16a is directed downward.
  • the body portion 27 constituting the proximal end side of the bending portion 26 in the sheath 16 is configured in a straight line.
  • the catheter 12 inserted into the body portion 27 of the sheath 16 remains straight, but when the catheter 12 is further advanced within the sheath 16, the shaft 18 of the catheter 12 is forced by the curved portion 26. Elastically deformed and curved.
  • the distal end portion of the shaft 18 of the catheter 12 protrudes from the distal end of the sheath 16 in a state of being directed in the same direction (downward) as the outlet direction of the sheath 16 (see FIG. 2B).
  • the sheath 16 allows the distal end portion of the catheter assembly 10 to be disposed at a treatment target site in the living body while the operator grasps and operates the proximal end side, and the shaft 18 of the catheter 12 is forcibly bent by the bending portion 26. It is only necessary to have an appropriate rigidity so that it can be made, for example, metal materials such as stainless steel, iron, iron alloy, aluminum, aluminum alloy, titanium, titanium alloy, polyethylene, polypropylene, ethylene- It is formed of various polymers such as polyolefin such as vinyl acetate copolymer, polyvinyl chloride, polymethyl methacrylate, polycarbonate, polybutadiene, polyamide, and polyester.
  • polyolefin such as vinyl acetate copolymer, polyvinyl chloride, polymethyl methacrylate, polycarbonate, polybutadiene, polyamide, and polyester.
  • the seal mechanism 14 (the isolation film 22 and the frame 24) in the present embodiment is formed in a circular shape.
  • the sealing mechanism 14 is not limited to a circular shape, and may have an elliptical shape, a rectangular shape, or the like.
  • the shape of the treatment target site is various, and the catheter 12 to which the seal mechanism 14 having a shape suitable for the shape is attached can be used according to the shape of the treatment target site.
  • the catheter assembly 10 is basically configured as described above, and the operation and effect thereof will be described below.
  • a cultured cell transplantation to a knee joint cartilage damaged part in an arthroscopic operation which is a typical use of the catheter assembly 10 will be described as an example.
  • the method of using the catheter assembly 10 according to this example includes the following steps (1) to (11). 4A to 5C, reference numeral 29 is cartilage, reference numeral 30 is a cartilage damage site, reference numeral 32 is an arthroscope, and reference numeral 33 is skin.
  • Dissection of the cartilage damage site Inject a liquid such as physiological saline into the knee joint where the cartilage damage site 30 exists to secure a work space, insert a dissection device from one side of the knee joint, The arthroscope 32 is inserted from the other side. Then, using a physiological saline or the like as a cleaning solution, while carving the inside of the knee joint under arthroscopy, the cartilage damaged part 30 is dissected (shaved) with the dissector to reveal the part to be transplanted with cells. Thereafter, the dissector is removed from the knee joint.
  • a liquid such as physiological saline into the knee joint where the cartilage damage site 30 exists to secure a work space
  • catheter 12 Insertion of catheter assembly
  • the catheter 12 is inserted into the sheath 16 through the puncture cavity (skin incision part) into which the dissection device has been inserted, and the seal mechanism 14 is reduced in diameter within the sheath 16 under arthroscopy.
  • the catheter assembly 10 is inserted.
  • FIG. 4A shows a state in which a small amount of liquid 35 remains in the cartilage injury site 30 after the liquid in the knee joint has been removed to some extent.
  • some removal of the liquid in the knee joint may be performed using a syringe and an injection needle before inserting the catheter assembly 10 into the knee joint.
  • the seal mechanism 14 is expanded, the seal mechanism 14 is pressed against the cartilage 29 around the cartilage damage site 30 to bring the lower surface of the seal mechanism 14 into close contact with the cartilage damage site 30.
  • the periphery of the cartilage damage site 30 may be pressed against the seal mechanism 14 using a rod-shaped pressing device 36 (see FIG. 4C).
  • a pressing device 36 having a C-shaped or U-shaped pressing portion 38 at the tip and a rod-like portion 40 that supports the pressing portion 38 is inserted into the sheath 16 and pressed from the tip opening 16a. The portion 38 is pressed against the upper surface of the seal mechanism 14 in the expanded state.
  • the lower surface of the seal mechanism 14 and the cartilage 29 around the cartilage damaged site 30 are in close contact with each other, and the cartilage damaged site 30 is isolated from other tissues (normal portions).
  • the inflow of the liquid into the cartilage damaged part 30 from other parts, that is, the parts other than the cartilage damaged part 30 is prevented.
  • the rod-like portion 40 of the pressing device 36 is bent in the same manner as the sheath 16 in a natural state so that the seal mechanism 14 can be easily pressed.
  • the pressing device 36 preferably has an appropriate rigidity so that the operating force from the operator's hand side can be suitably transmitted to the distal end side.
  • any one of the pressing devices 36 exemplified above as the constituent material of the sheath 16 is used. Or it may be composed of a plurality of materials.
  • the sealing mechanism 14 is pressed by the pressing device 36 passed through the sheath 16 as shown in FIG. 4C, the rod-shaped portion 40 is elastically deformed in order to insert the pressing device 36 having the bent rod-shaped portion 40 into the sheath 16.
  • the pressing device 36 is required to have a certain degree of flexibility. Instead of inserting the pressing device 36 into the sheath 16, another lumen may be provided in the sheath 16, and the pressing device 36 may be inserted into the knee joint through the other lumen to press the sealing mechanism 14. .
  • the seal mechanism 14 is pressed around the cartilage damaged site 30 to maintain the isolated state of the cartilage damaged site 30 from other tissues.
  • the suction device connected to the hub 20 is operated to completely remove the liquid 35 remaining on the cartilage injury site 30 (see FIG. 4D).
  • the isolation film 22 has transparency, even when the cartilage damage site 30 is covered by the seal mechanism 14, it is possible to confirm the state of sucking the liquid in the cartilage damage site 30 with the arthroscope 32.
  • the lumen 18a of the catheter 12 has a shaft having a diameter smaller than that of the lumen 18a.
  • Another catheter hereinafter referred to as “aspiration catheter”
  • the distal end of the aspiration catheter is protruded from the distal end of the catheter 12, and the liquid 35 on the cartilage injury site 30 is aspirated through the aspiration catheter. May be. Thereby, the suction of the liquid 35 away from the distal end of the catheter 12 can be reliably performed.
  • the isolation film 22 has transparency, even when the cartilage damage site 30 is covered by the sealing mechanism 14, it is possible to confirm the state in which the cell suspension 42 is injected into the cartilage damage site 30 under an arthroscopic view. .
  • the inner peripheral surface of the lumen 18a of the catheter 12 or the inner peripheral surface of the lumen of the suction catheter is hydrophobic because the cell suspension 42 can be injected without loss.
  • the plate is allowed to stand for a predetermined time (for example, 10 minutes). As described above, since the cartilage damage site 30 and other tissues are isolated from each other by the seal mechanism 14, while the cell suspension 42 is allowed to stand still, the part other than the cartilage damage site 30 is used. The liquid does not flow into the cartilage damage site 30.
  • the following cell transplantation method can be performed by using the catheter assembly 10 according to the present embodiment. That is, the cell transplantation method is: A step of preparing a catheter assembly 10 including a hollow shaft 18, a contractible and expandable seal mechanism 14 provided in the vicinity of the distal end portion of the shaft 18, and a sheath 16 that can accommodate the seal mechanism 14.
  • the seal mechanism 14 is expanded in vivo by a simple operation from outside the living body, and the expanded seal mechanism 14 is disposed around the treatment target site.
  • the treatment target region can be isolated from other tissues, thereby preventing liquid from flowing into the treatment target region. Therefore, the treatment for the treatment target site can be performed easily and reliably without reducing the therapeutic effect.
  • the seal mechanism 14 includes an isolation film 22 whose inner periphery is joined to the outer periphery of the shaft 18 and a frame 24 that supports the isolation film 22.
  • the adhesion of the seal mechanism 14 can be improved, and the penetration of the liquid from the outside to the inside of the treatment target site can be more preferably prevented.
  • the frame 24 is a ring-shaped flexible member provided on the outer peripheral edge of the isolation film 22, and the seal mechanism 14 is elastic when it comes out of the sheath 16. Self-expand by resilience. That is, the seal mechanism 14 that moves the catheter 12 in the distal direction relative to the sheath 16 is automatically expanded. For this reason, the seal mechanism 14 can be expanded by a single operation without requiring a separate expansion operation, and the operability is excellent.
  • FIG. 6 is a partially omitted perspective view of the catheter assembly 10a according to the second embodiment of the present invention.
  • elements having the same or similar functions and effects as those of the catheter assembly 10 according to the first embodiment are denoted by the same reference numerals, and detailed description thereof is omitted. To do.
  • FIG. 7A is a longitudinal sectional view of the sealing mechanism 50 in a contracted state
  • FIG. 7B is a longitudinal sectional view of the sealing mechanism 50 in an expanded state
  • FIG. 8 is a perspective view of the seal mechanism 50 in an expanded state.
  • the seal mechanism 50 includes a separation film 52 joined to the outer periphery of the shaft 18, a plurality of frames 54 that support the separation film 52, and the plurality of frames 54 connected to the shaft 18. And a slidable connecting member 56.
  • the isolation film 52 of the seal mechanism 50 is configured in the same manner as the isolation film 22 in the first embodiment.
  • a plurality of the frames 54 are provided around the shaft 18 (eight in the illustrated example), and expand radially when the seal mechanism 50 is expanded (see FIGS. 7B and 8).
  • one end of the frame 54 is rotatably connected to the connecting member 56, and the other end is connected to the outer peripheral edge of the isolation film 52.
  • the frame 54 preferably has an appropriate rigidity so that the isolation film 52 can be reliably deployed.
  • the frame 54 can be made of the same material as the frame 54 in the first embodiment.
  • the connecting member 56 is formed in a ring shape, and the shaft 18 is inserted inside the ring shape and can be displaced along the shaft 18.
  • the frame 54 described above is rotatably connected to the outer peripheral portion of the connecting member 56.
  • the isolation film 52 expands and a plurality of frames 54 radiate at a position closer to the proximal end of the shaft 18 than the isolation film 52.
  • a lock portion 60 is provided that engages the connecting member 56 to prevent (restrict) movement of the connecting member 56 in the proximal direction.
  • the lock portion 60 is made of, for example, an elastic body and has a tapered surface that is inclined so that the distance (height) from the outer peripheral surface of the shaft 18 increases toward the distal end of the shaft 18.
  • the connecting member 56 In the state where the seal mechanism 50 is contracted (the state shown in FIG. 7A), the connecting member 56 is located away from the lock portion 60 in the proximal direction of the shaft 18.
  • the connecting member 56 moves in the proximal direction of the shaft 18 when the seal mechanism 50 is expanded (deployed)
  • the connecting member 56 eventually gets over the lock portion 60 and is closer to the distal end side of the shaft 18 than the lock portion 60. Displaces up to (between the lock portion 60 and the isolation film 52) (see FIG. 7B).
  • the connecting member 56 gets over the lock part 60, the lock part 60 is elastically compressed and deformed.
  • the connecting member 56 gets over the lock part 60, the lock part 60 is restored to its original shape. For this reason, the connecting member 56 is locked by the end surface on the distal end side of the lock portion 60, and the connecting member 56 is in a locked state in which the connecting member 56 is prevented from moving in the proximal direction of the shaft 18.
  • the catheter assembly 10a according to the present embodiment is basically configured as described above, and the operation and effect thereof will be described below.
  • FIGS. 9A to 10D an example of cultured cell transplantation into a knee joint cartilage injury site in arthroscopic surgery, which is a typical use of the catheter assembly 10a, will be described.
  • the method of using the catheter assembly 10a according to this example includes the following steps (1a) to (11a).
  • FIG. 9A shows a state in which a small amount of liquid 35 remains in the cartilage injury site 30 after the liquid in the knee joint has been removed to some extent. It should be noted that some removal of the liquid in the knee joint may be performed using a syringe and an injection needle before inserting the catheter assembly 10a into the knee joint, instead of using the catheter assembly 10a.
  • the pressing device 36 is inserted into the sheath 16, and the connecting member 56 or the frame 54 is pushed downward by the pressing portion 38 provided at the distal end of the pressing device 36, and the connecting member 56 gets over the lock portion 60 and locks 60.
  • the connecting member 56 is displaced in the direction of the distal end of the shaft 18 until it is locked to the position (see FIG. 9C).
  • the isolation film 52 is expanded, and the seal mechanism 50 is expanded as shown in FIG. 9C.
  • the above-described operation of providing another lumen in the sheath 16 inserting the pressing device 36 into the knee joint through the other lumen, and expanding the seal mechanism 50. May be performed.
  • the following cell transplantation method can be performed by using the catheter assembly 10a according to the present embodiment. That is, the cell transplantation method is: A step of preparing a catheter assembly 10 a including a hollow shaft 18, a contractible and expandable seal mechanism 50 provided in the vicinity of the tip of the shaft 18, and a sheath 16 that can accommodate the seal mechanism 50.
  • a plurality of frames 54 are provided around the shaft 18 and expand radially when the seal mechanism 50 is expanded.
  • the overall rigidity can be increased, and the adhesion between the seal mechanism 50 and the periphery of the treatment target site can be effectively increased.
  • the seal mechanism 50 includes the connecting member 56 that is connected to the plurality of frames 54 and can be displaced along the shaft 18, so that the plurality of frames 54 can be radially developed with good balance. . For this reason, the adhesiveness of the seal mechanism 50 and the circumference
  • annular seal member 72 may be provided on the lower surface of the isolation film 52 (the surface on the side in contact with the treatment target site).
  • the seal member 72 is configured by, for example, an O-ring, and is disposed along the outer peripheral edge portion of the lower surface of the isolation film 22.
  • a flexible annular porous body may be provided on the outer peripheral edge of the lower surface of the isolation film 22.
  • the porous body can be elastically deformed so as to follow the surface shape (uneven shape, etc.) around the treatment target site, so that it can be well around the treatment target site. Since it adheres closely, the sealing performance between the sealing mechanism 70 and a treatment object site
  • An illumination lumen 83 into which an optical fiber or the like connected to a light source can be inserted may be provided.
  • the imaging means is inserted into the imaging lumen 82 and the light irradiation means is inserted into the illumination lumen 83, whereby the catheter
  • the assemblies 10 and 10a can be reliably disposed at the treatment target site.
  • the lower surface of the isolation film 22 (the surface on the side in contact with the treatment target site) may be configured with, for example, a mirror surface or white so as to easily reflect light.
  • the present invention has been described with reference to preferred embodiments. However, the present invention is not limited to the above-described embodiments, and various modifications can be made without departing from the scope of the present invention.
  • an arthroscopic cell transplantation operation at the knee joint is given as an application of the catheter assembly 10, 10a, but the present invention is not limited to this. That is, the catheter assembly 10, 10a according to the present invention can be applied to any surgical method that involves draining a liquid.
  • the catheter assemblies 10 and 10a according to the present invention can be used for endoscopic surgery such as intracerebral, intraperitoneal, carpal tunnel, shoulder joint, elbow joint, spine, etc., and drainage of pleural effusion and ascites.

Abstract

A catheter assembly (10) is provided with a hollow shaft (18) which has a lumen (18a), a seal mechanism (14) which is provided on the outer periphery of the vicinity of the distal end of the shaft (18) and which can be expanded and contracted, and a sheath (16) through which the shaft (18) can be inserted and which can contain the contracted seal mechanism (14). When the expanded seal mechanism (14) is pressed in a living organism against the periphery of a part to be treated (a damaged part (30) of a cartilage), the inside and outside of the part to be treated are separated by the seal mechanism (14).

Description

カテーテル組立体Catheter assembly
 本発明は、生体内において処置対象部位とその他の組織とを隔離するための隔離機構を備えたカテーテル組立体に関する。 The present invention relates to a catheter assembly including an isolation mechanism for isolating a treatment target site and other tissues in a living body.
 軟骨損傷部位(軟骨欠損部)の再生治療方法の1つとして、培養した細胞や採取した骨髄液を濃縮し調整した骨髄由来細胞を関節鏡視下で移植する方法がある。例えば、文献「臨床整形外科」(関矢一郎、Vol.45、No.9、医学書院、2010年9月25日、p.791-795)には以下のような具体例が示されている。患者から採取した滑膜細胞を2週間培養し、軟骨損傷部位を関節鏡視下で郭清(シェービング)した後、針とシリンジを用いて軟骨損傷部位に0.1mLの細胞懸濁液を注入する。ここで注意すべき点として、細胞懸濁液を膝の軟骨損傷部位に移植する際、関節内液を十分に除去しなければ、細胞が分散してしまい軟骨損傷部位に選択的に留まらず軟骨再生効果が得られない懸念がある。 One method of regenerative treatment of cartilage damage sites (cartilage defects) is a method of transplanting cultured cells and bone marrow-derived cells prepared by concentrating collected bone marrow fluid under arthroscopy. For example, the following “Clinical Orthopedic Surgery” (Ichiro Sekiya, Vol. 45, No. 9, Medical School, September 25, 2010, p. 791-795) shows the following specific examples. Synovial cells collected from patients are cultured for 2 weeks, and the cartilage damage site is dissected (shaved) under arthroscopy, and then 0.1 mL of cell suspension is injected into the cartilage damage site using a needle and syringe. To do. It should be noted that when the cell suspension is transplanted to the cartilage injury site of the knee, if the intra-articular fluid is not removed sufficiently, the cells will disperse and do not stay selectively at the cartilage injury site. There is a concern that the regeneration effect cannot be obtained.
 そこで、針とシリンジ等を用いて関節内の液体を可能な限り吸引し、除去する必要があるが、関節鏡や針により軟骨損傷部位だけでなく健康な軟骨まで損傷してしまう危険性がある。また、関節内には液体の入り込む隙間があり、完全に液体を除去することが困難であることから、液体除去作業の実施からある程度時間が経つと関節内に残存していた液体が処置対象部位に流入するため、何度もシリンジ等で液体を除去する必要があった。 Therefore, it is necessary to suck and remove the liquid in the joint as much as possible using a needle and syringe, etc., but there is a risk of damaging not only the cartilage damaged site but also healthy cartilage by the arthroscope or needle . In addition, there is a gap for the liquid to enter in the joint, and it is difficult to completely remove the liquid. Therefore, after a certain amount of time has passed since the liquid removal operation, the liquid remaining in the joint is treated. Therefore, it was necessary to remove the liquid many times with a syringe or the like.
 本発明はこのような課題を考慮してなされたものであり、処置対象部位に対して、生体外からの簡易な操作によって、処置対象部位をその他の組織から隔離することができ、これにより処置対象部位への液体の流入を阻止することが可能なカテーテル組立体を提供することを目的とする。 The present invention has been made in consideration of such a problem, and the treatment target region can be isolated from other tissues by a simple operation from outside the living body, thereby treating the treatment target region. An object of the present invention is to provide a catheter assembly capable of preventing liquid from flowing into a target site.
 上記の目的を達成するため、本発明に係るカテーテル組立体は、ルーメンを有する中空状のシャフトと、前記シャフトの先端部近傍の外周に設けられ、収縮及び拡張が可能なシール機構と、前記シャフトが挿通可能であるとともに、収縮状態の前記シール機構を収容可能なシースとを備え、生体内で、拡張した前記シール機構が処置対象部位の周囲に押圧されたとき、前記処置対象部位の内側と外側とを前記シール機構により隔離するように構成されていることを特徴とする。 In order to achieve the above object, a catheter assembly according to the present invention includes a hollow shaft having a lumen, a seal mechanism provided on the outer periphery in the vicinity of the tip of the shaft and capable of contraction and expansion, and the shaft. And a sheath that can accommodate the contracted seal mechanism, and when the expanded seal mechanism is pressed around the treatment target site in a living body, The outside is separated from the outside by the sealing mechanism.
 上記の構成によれば、生体外からの簡易な操作によって、生体内でシール機構を拡張させ、拡張させたシール機構を処置対象部位の周囲に押し当てることにより、処置対象部位をその他の組織から隔離し、これにより処置対象部位への液体の流入を阻止することができる。よって、処置対象部位に対する治療を、当該治療効果を低減することなく、簡易且つ確実に行うことができる。 According to the above-described configuration, the treatment target region is expanded from other tissues by expanding the seal mechanism in the living body by a simple operation from outside the living body, and pressing the expanded seal mechanism around the treatment target region. It isolates and can prevent the inflow of the liquid to a treatment object site | part by this. Therefore, the treatment for the treatment target site can be performed easily and reliably without reducing the therapeutic effect.
 上記のカテーテル組立体において、前記シール機構は、前記シャフトの外周に接合された隔離膜と、前記隔離膜を支持するフレームとを有するとよい。この構成によれば、処置対象部位の周囲に対するシール機構の密着性を向上でき、処置対象部位の外側から内側への液体の浸入を一層好適に防止できる。 In the above catheter assembly, the sealing mechanism may include an isolation film joined to an outer periphery of the shaft and a frame that supports the isolation film. According to this configuration, it is possible to improve the adhesion of the seal mechanism to the periphery of the treatment target site, and it is possible to more suitably prevent liquid from entering from the outside to the inside of the treatment target site.
 上記のカテーテル組立体において、前記フレームは、前記隔離膜の外周縁部に設けられたリング状の可撓性を有する部材であり、前記シール機構は、前記シースから出た際に、前記フレームの弾性復元力により自己拡張する構成であるとよい。この構成によれば、別途の拡張操作を要することなく、単一の操作でシール機構を拡張させることができ、操作性に優れる。 In the above catheter assembly, the frame is a ring-shaped flexible member provided on an outer peripheral edge of the isolation membrane, and the seal mechanism is configured so that when it comes out of the sheath, the frame It is good to be a structure which self-expands by elastic restoring force. According to this configuration, the seal mechanism can be expanded by a single operation without requiring a separate expansion operation, and the operability is excellent.
 上記のカテーテル組立体において、前記フレームは、前記シャフトの周囲に複数設けられ、前記シール機構の拡張時に放射状に展開する構成であるとよい。この構成によれば、拡張時におけるシール機構全体の剛性を高めることができ、シール機構と処置対象部位の周囲との密着性を効果的に高めることができる。 In the above catheter assembly, a plurality of the frames may be provided around the shaft, and may be configured to expand radially when the seal mechanism is expanded. According to this configuration, the rigidity of the entire seal mechanism at the time of expansion can be increased, and the adhesion between the seal mechanism and the periphery of the treatment target site can be effectively increased.
 上記のカテーテル組立体において、前記シール機構は、前記複数のフレームに連結されるとともに前記隔離膜よりも前記シャフトの基端側で前記シャフトに沿って変位自在な連結部材を備えるとよい。この構成によれば、複数のフレームをバランスよく放射状に展開させることができる。よって、シール機構と処置対象部位の周囲との密着性を効果的に高めることができる。 In the above-described catheter assembly, the sealing mechanism may include a connecting member that is connected to the plurality of frames and that is displaceable along the shaft on the proximal end side of the shaft with respect to the isolation film. According to this configuration, a plurality of frames can be developed radially with good balance. Therefore, the adhesion between the seal mechanism and the periphery of the treatment target site can be effectively enhanced.
 上記のカテーテル組立体において、前記シャフトの外周部には、連結部材を解除可能に係止するロック部が設けられると、シール機構の拡張状態を確実に維持できる。 In the above catheter assembly, when the outer peripheral portion of the shaft is provided with a lock portion for releasably engaging the connecting member, the expanded state of the seal mechanism can be reliably maintained.
 上記のカテーテル組立体において、前記シール機構を押圧する棒状の押圧デバイスを備えると、シール機構と処置対象部位の周囲との密着性を好適に高めることができる。 In the above catheter assembly, when a rod-like pressing device that presses the sealing mechanism is provided, the adhesion between the sealing mechanism and the periphery of the treatment target site can be suitably increased.
 上記のカテーテル組立体において、前記シースは、長手方向の途中部位が屈曲しており、前記押圧デバイスは、前記シースに沿って曲がる可撓性を有すると、例えば、関節鏡下手術での膝関節軟骨損傷部位への培養細胞移植のように、カテーテル組立体の挿入方向に対して屈曲した方向に処置対象部位がある処置を好適に実施することができる。 In the above catheter assembly, the sheath has a bent portion in the longitudinal direction, and the pressing device has flexibility to bend along the sheath, for example, a knee joint in arthroscopic surgery As in the case of transplantation of cultured cells to a cartilage injury site, a treatment in which the treatment target site is in a direction bent with respect to the insertion direction of the catheter assembly can be suitably performed.
 上記のカテーテル組立体において、前記ルーメンの内周面は、疎水性を有すると、細胞懸濁液を損失なく注入できる。 In the above catheter assembly, if the inner peripheral surface of the lumen is hydrophobic, the cell suspension can be injected without loss.
 上記のカテーテル組立体において、前記シール機構は、透明性を有すると、内視鏡又は関節鏡により、液体を吸引する様子や、細胞注入の様子を確実に観察できる。 In the above catheter assembly, when the sealing mechanism is transparent, it is possible to reliably observe the state of sucking liquid and the state of cell injection by an endoscope or an arthroscope.
 上記のカテーテル組立体において、前記シール機構は、前記処置対象部位に接触する側に、環状のシール部材又は多孔質体を有すると、シール機構と処置対象部位との間のシール性を高め、処置対象部位への液体の流入を一層確実に阻止することができる。 In the above catheter assembly, when the seal mechanism has an annular seal member or a porous body on the side in contact with the treatment target site, the sealing performance between the seal mechanism and the treatment target site is improved, and the treatment is performed. It is possible to more reliably prevent the liquid from flowing into the target site.
 上記のカテーテル組立体において、前記シャフトは、撮像手段を挿入可能な撮像用ルーメンと、光照射手段を挿入可能な照明用ルーメンとを有すると、内視鏡又は関節鏡を使用しない場合でも、カテーテル組立体を確実に処置対象部位に配置することができる。また、損傷部位の様子を直接観察することができ、液体を完全に除去したことを確認したうえで細胞注入でき、確実に治療を行うことができる。 In the above catheter assembly, the shaft has an imaging lumen into which the imaging means can be inserted and an illumination lumen into which the light irradiation means can be inserted, so that the catheter can be used even when an endoscope or an arthroscope is not used. The assembly can be reliably placed at the treatment target site. In addition, the state of the damaged site can be directly observed, and after confirming that the liquid has been completely removed, cells can be injected, and treatment can be performed reliably.
 上記のカテーテル組立体において、前記シャフトは、拡張状態での前記隔離膜の略中心を貫通すると、処置対象部位の略中央から細胞を注入することができる。 In the above catheter assembly, when the shaft passes through the approximate center of the isolation membrane in the expanded state, cells can be injected from the approximate center of the treatment target site.
 本発明のカテーテル組立体によれば、処置対象部位に対して、生体外からの簡易な操作によって、処置対象部位をその他の組織から隔離することができ、これにより処置対象部位への液体の流入を阻止することが可能となる。 According to the catheter assembly of the present invention, the treatment target site can be isolated from other tissues by a simple operation from outside the living body with respect to the treatment target site, thereby allowing the liquid to flow into the treatment target site. Can be prevented.
本発明の第1実施形態に係るカテーテル組立体の一部省略斜視図である。1 is a partially omitted perspective view of a catheter assembly according to a first embodiment of the present invention. 図2Aは、図1に示したカテーテル組立体のシール機構の収縮状態での一部省略縦断面図であり、図2Bは、図1に示したカテーテル組立体のシール機構の拡張状態での一部省略縦断面図である。2A is a partially omitted vertical cross-sectional view of the sealing mechanism of the catheter assembly shown in FIG. 1 in a contracted state, and FIG. 2B is a diagram of an expanded state of the sealing mechanism of the catheter assembly shown in FIG. FIG. 拡張したシール機構の斜視図である。It is a perspective view of the expanded sealing mechanism. 図4Aは、第1実施形態に係るカテーテル組立体の使用方法を説明する第1の図であり、図4Bは、第1実施形態に係るカテーテル組立体の使用方法を説明する第2の図であり、図4Cは、第1実施形態に係るカテーテル組立体の使用方法を説明する第3の図であり、図4Dは、第1実施形態に係るカテーテル組立体の使用方法を説明する第4の図である。FIG. 4A is a first diagram illustrating a method of using the catheter assembly according to the first embodiment, and FIG. 4B is a second diagram illustrating a method of using the catheter assembly according to the first embodiment. FIG. 4C is a third diagram illustrating a method of using the catheter assembly according to the first embodiment, and FIG. 4D is a fourth diagram illustrating a method of using the catheter assembly according to the first embodiment. FIG. 図5Aは、第1実施形態に係るカテーテル組立体の使用方法を説明する第5の図であり、図5Bは、第1実施形態に係るカテーテル組立体の使用方法を説明する第6の図であり、図5Cは、第1実施形態に係るカテーテル組立体の使用方法を説明する第7の図である。FIG. 5A is a fifth diagram illustrating a method of using the catheter assembly according to the first embodiment, and FIG. 5B is a sixth diagram illustrating a method of using the catheter assembly according to the first embodiment. FIG. 5C is a seventh diagram illustrating a method of using the catheter assembly according to the first embodiment. 本発明の第2実施形態に係るカテーテル組立体の一部省略斜視図である。It is a partially-omission perspective view of the catheter assembly which concerns on 2nd Embodiment of this invention. 図7Aは、第2実施形態に係るカテーテル組立体のシール機構の収縮状態での縦断面図であり、図7Bは、第2実施形態に係るカテーテル組立体のシール機構の拡張状態での縦断面図である。FIG. 7A is a longitudinal sectional view in a contracted state of the sealing mechanism of the catheter assembly according to the second embodiment, and FIG. 7B is a longitudinal sectional view in an expanded state of the sealing mechanism of the catheter assembly according to the second embodiment. FIG. 第2実施形態に係るカテーテル組立体におけるシール機構の拡張状態での斜視図である。It is a perspective view in the expansion state of the seal mechanism in the catheter assembly concerning a 2nd embodiment. 図9Aは、第2実施形態に係るカテーテル組立体の使用方法を説明する第1の図であり、図9Bは、第2実施形態に係るカテーテル組立体の使用方法を説明する第2の図であり、図9Cは、第2実施形態に係るカテーテル組立体の使用方法を説明する第3の図であり、図9Dは、第2実施形態に係るカテーテル組立体の使用方法を説明する第4の図である。FIG. 9A is a first diagram illustrating a method for using the catheter assembly according to the second embodiment, and FIG. 9B is a second diagram illustrating a method for using the catheter assembly according to the second embodiment. FIG. 9C is a third diagram illustrating a method of using the catheter assembly according to the second embodiment, and FIG. 9D is a fourth diagram illustrating a method of using the catheter assembly according to the second embodiment. FIG. 図10Aは、第2実施形態に係るカテーテル組立体の使用方法を説明する第5の図であり、図10Bは、第2実施形態に係るカテーテル組立体の使用方法を説明する第6の図であり、図10Cは、第2実施形態に係るカテーテル組立体の使用方法を説明する第7の図であり、図10Dは、第2実施形態に係るカテーテル組立体の使用方法を説明する第8の図である。FIG. 10A is a fifth diagram for explaining how to use the catheter assembly according to the second embodiment, and FIG. 10B is a sixth diagram for explaining how to use the catheter assembly according to the second embodiment. FIG. 10C is a seventh diagram illustrating a method for using the catheter assembly according to the second embodiment, and FIG. 10D is an eighth diagram illustrating a method for using the catheter assembly according to the second embodiment. FIG. 図11Aは、変形例に係るシール機構を備えたカテーテル組立体の先端部の縦断面図であり、図11Bは、変形例に係るシャフトを備えたカテーテル組立体の先端部の縦断面図である。FIG. 11A is a longitudinal sectional view of a distal end portion of a catheter assembly provided with a seal mechanism according to a modification, and FIG. 11B is a longitudinal sectional view of a distal end portion of the catheter assembly provided with a shaft according to the modification. .
 以下、本発明に係るカテーテル組立体について好適な実施形態を挙げ、添付の図面を参照しながら説明する。なお、説明の都合上、個々の図面における構成要素同士の寸法の比率、及び複数の図面における同一の構成要素同士の寸法の比率は適宜変更されており必ずしも現実の比率とは一致しないものとする。 Hereinafter, preferred embodiments of the catheter assembly according to the present invention will be described with reference to the accompanying drawings. For convenience of explanation, the ratio of dimensions between components in each drawing and the ratio of dimensions between components in the drawings are appropriately changed and do not necessarily match the actual ratio. .
[第1実施形態]
 図1は、本発明の第1実施形態に係るカテーテル組立体10の一部省略斜視図である。このカテーテル組立体10は、カテーテル12と、カテーテル12の先端部近傍に設けられた収縮及び拡張可能なシール機構14と、カテーテル12とシール機構14とが挿通可能なシース16とを備え、生体内で、拡張したシール機構14を処置対象部位の周囲に押し当てることにより、処置対象部位の内部をその他の部位から隔離するように構成されている。図1では、シール機構14がシース16内に収容された状態が示されている。
[First Embodiment]
FIG. 1 is a partially omitted perspective view of a catheter assembly 10 according to a first embodiment of the present invention. The catheter assembly 10 includes a catheter 12, a contractible and expandable seal mechanism 14 provided near the distal end of the catheter 12, and a sheath 16 through which the catheter 12 and the seal mechanism 14 can be inserted. Thus, the expanded seal mechanism 14 is pressed against the periphery of the treatment target site to isolate the inside of the treatment target site from other sites. FIG. 1 shows a state in which the seal mechanism 14 is accommodated in the sheath 16.
 図2Aは、カテーテル組立体10のシール機構14が収縮した状態での一部省略縦断面図であり、図2Bは、カテーテル組立体10のシール機構14が拡張した状態での一部省略縦断面図である。図3は、拡張状態のシール機構14の斜視図である。図1~図3に示すように、カテーテル12は、カテーテル12の本体を構成する中空状のシャフト18と、シャフト18の基端部に接続された中空状のハブ20とを有する。シャフト18は、可撓性を有する管状部材であり、ルーメン18aが軸線方向に貫通形成されている。 FIG. 2A is a partially omitted longitudinal sectional view of the catheter assembly 10 with the sealing mechanism 14 contracted, and FIG. 2B is a partially omitted longitudinal section of the catheter assembly 10 with the sealing mechanism 14 expanded. FIG. FIG. 3 is a perspective view of the seal mechanism 14 in the expanded state. As shown in FIGS. 1 to 3, the catheter 12 includes a hollow shaft 18 constituting the main body of the catheter 12 and a hollow hub 20 connected to the proximal end portion of the shaft 18. The shaft 18 is a flexible tubular member, and a lumen 18a is formed to penetrate in the axial direction.
 シャフト18の寸法は、それが使用される生体内及び処置対象部位の大きさに応じて適宜選択されるが、特に、膝関節での関節鏡視下手術に使用される場合には、外径が1~10mm程度、内径が0.5~9.5mm程度、全長が20~300mm程度に設定されるのが好ましい。 The dimension of the shaft 18 is appropriately selected according to the living body in which the shaft 18 is used and the size of the treatment target site. In particular, when the shaft 18 is used for arthroscopic surgery at the knee joint, the outer diameter is selected. Is preferably set to about 1 to 10 mm, the inner diameter is set to about 0.5 to 9.5 mm, and the total length is set to about 20 to 300 mm.
 シャフト18の基端部に連結されたハブ20は、シャフト18のルーメン18aに連通するハブルーメン20aが軸線方向に貫通形成されている。ハブ20は、液体吸引のための陰圧を発生させる吸引装置と、細胞懸濁液をカテーテル12に供給するための注入具が接続可能に構成されている。吸引装置は、例えば、真空ポンプと回収容器を備えた機構、アスピレータ、シリンジ等である。注入具は、例えば、細胞懸濁液が充填されたシリンジである。 The hub 20 connected to the base end portion of the shaft 18 has a hub lumen 20a communicating with the lumen 18a of the shaft 18 penetrating in the axial direction. The hub 20 is configured to be connectable to a suction device that generates a negative pressure for liquid suction and an injection tool for supplying a cell suspension to the catheter 12. The suction device is, for example, a mechanism including a vacuum pump and a collection container, an aspirator, a syringe, or the like. The injection tool is, for example, a syringe filled with a cell suspension.
 カテーテル12を構成するシャフト18及びハブ20は、例えば、エチレン-テトラフルオロエチレン共重合体(ETFE)、ポリエーテルナイロン、ポリアミド、ポリエステル、ポリウレタン、ポリエチレン、ポリプロピレン、ポリ塩化ビニル等の各種材料で形成される。 The shaft 18 and the hub 20 constituting the catheter 12 are made of various materials such as ethylene-tetrafluoroethylene copolymer (ETFE), polyether nylon, polyamide, polyester, polyurethane, polyethylene, polypropylene, and polyvinyl chloride. The
 本実施形態において、シール機構14は、その内周部がシャフト18の外周に接合された隔離膜22と、隔離膜22を支持するフレーム24とを有し、拡張した状態で処置対象部位(例えば、軟骨損傷部位)に押し付けることにより、処置対象部位を密閉するように構成されている。隔離膜22は、シース16内に収容可能な大きさに容易に折り畳めるような柔軟性を有するシート状の部材である。カテーテル12のシャフト18は、隔離膜22の中心部に設けられた孔を貫通しており、隔離膜22が拡張した状態ではシャフト18の先端部が隔離膜22から突出する。 In the present embodiment, the seal mechanism 14 includes an isolation film 22 whose inner periphery is joined to the outer periphery of the shaft 18 and a frame 24 that supports the isolation film 22, and in a expanded state, a treatment target site (for example, The site to be treated is sealed by being pressed against the cartilage injury site. The isolation film 22 is a sheet-like member having flexibility such that it can be easily folded into a size that can be accommodated in the sheath 16. The shaft 18 of the catheter 12 passes through a hole provided in the central portion of the isolation film 22, and the distal end portion of the shaft 18 protrudes from the isolation film 22 when the isolation film 22 is expanded.
 隔離膜22の寸法は、それが使用される生体内及び処置対象部位の大きさに応じて適宜選択されるが、特に、膝関節での関節鏡視下手術に使用される場合には、外径が1.5~40mm程度に設定されるのが好ましい。 The size of the isolation membrane 22 is appropriately selected according to the living body in which the isolation membrane 22 is used and the size of the treatment target site, and in particular, when used for arthroscopic surgery at the knee joint, The diameter is preferably set to about 1.5 to 40 mm.
 隔離膜22は、処置対象部位を密閉することができる素材からなり、例えば、塩化ビニル、ポリウレタンエラストマー、スチレン-エチレン-ブチレン-スチレン共重合体(SEBS)、スチレン-エチレン-プロピレン-スチレン共重合体(SEPS)等の熱可塑性エラストマー、ナイロン、PET等の熱可塑性樹脂、又は、ゴム、シリコーンエラストマー等の熱硬化性樹脂を用いることが好ましい。また、これらを適宜組み合わせて用いることも可能である。また、隔離膜22は、シール機構14により処置対象部位を覆った状態で処置対象部位内の液体を吸引する様子や細胞注入を行う様子を内視鏡又は関節鏡で視認できるように、透明性を有する。 The isolation film 22 is made of a material capable of sealing the treatment target site, and includes, for example, vinyl chloride, polyurethane elastomer, styrene-ethylene-butylene-styrene copolymer (SEBS), styrene-ethylene-propylene-styrene copolymer. It is preferable to use a thermoplastic elastomer such as (SEPS), a thermoplastic resin such as nylon or PET, or a thermosetting resin such as rubber or silicone elastomer. Moreover, it is also possible to use these in combination as appropriate. In addition, the isolation film 22 is transparent so that a state in which the liquid in the treatment target region is sucked and a state in which cells are injected can be visually confirmed with an endoscope or an arthroscope while the treatment target region is covered by the seal mechanism 14. Have
 フレーム24は、隔離膜22の外周縁部に設けられ、隔離膜22を支持するものであり、可撓性を有するリング状の部材である。シール機構14は、可撓性を有するフレーム24を備えるため、図2Aに示すように、フレーム24の弾性変形によって収縮することにより、シャフト18とともにシース16内に挿入されることが可能であり、図2Bに示すように、シース16の先端から出た際にはフレーム24の弾性復元力により自己拡張することが可能である。 The frame 24 is provided on the outer peripheral edge portion of the isolation film 22, supports the isolation film 22, and is a ring-shaped member having flexibility. Since the seal mechanism 14 includes a flexible frame 24, the seal mechanism 14 can be inserted into the sheath 16 together with the shaft 18 by contracting due to elastic deformation of the frame 24, as shown in FIG. As shown in FIG. 2B, when the sheath 16 comes out from the distal end, it can be expanded by the elastic restoring force of the frame 24.
 このようなフレーム24は、弾性変形可能な柔軟性を有し且つ形状が弾性的に復元可能であればよく、例えば、ステンレス鋼、タンタル、コバルト合金、チタン合金等の弾性又は超弾性を有する金属材料、或いは、ポリエチレン、ポリプロピレン、エチレン-酢酸ビニル共重合体等のポリオレフィン、ポリ塩化ビニル、ポリメチルメタクリレート、ポリカーボネート、ポリブタジエン、ポリアミド、ポリエステル等の各種ポリマーにより形成される。特に、フレーム24の構成材料が、チタン合金のような超弾性合金(形状記憶合金)であると、シール機構14がシース16から出た際に確実に拡張することができるため、好ましい。 Such a frame 24 is only required to have elasticity that can be elastically deformed and to be elastically recoverable in shape, for example, a metal having elasticity or superelasticity such as stainless steel, tantalum, cobalt alloy, titanium alloy or the like. It is made of a material or various polymers such as polyolefin such as polyethylene, polypropylene and ethylene-vinyl acetate copolymer, polyvinyl chloride, polymethyl methacrylate, polycarbonate, polybutadiene, polyamide and polyester. In particular, it is preferable that the constituent material of the frame 24 is a superelastic alloy (shape memory alloy) such as a titanium alloy because the seal mechanism 14 can be reliably expanded when it comes out of the sheath 16.
 シース16は、カテーテル12と収縮状態のシール機構14を挿入させることが可能なルーメン16bを有する、両端が開口した管状の部材である。本実施形態において、シース16は、先端部近傍で下方に湾曲して、先端開口16aが下方を指向している。シース16における湾曲部26よりも基端側を構成する胴体部27は、直線状に構成されている。図2Aのように、シース16の胴体部27に挿入されたカテーテル12は、直線状を維持するが、シース16内でカテーテル12を更に前進させると、カテーテル12のシャフト18は湾曲部26によって強制的に弾性変形させられて、湾曲する。これにより、カテーテル12のシャフト18の先端部は、シース16の出口方向と同じ方向(下方)に指向された状態で、シース16の先端から突出する(図2B参照)。 The sheath 16 is a tubular member having a lumen 16b into which the catheter 12 and the contracted seal mechanism 14 can be inserted, and both ends are open. In the present embodiment, the sheath 16 is bent downward in the vicinity of the distal end portion, and the distal end opening 16a is directed downward. The body portion 27 constituting the proximal end side of the bending portion 26 in the sheath 16 is configured in a straight line. As shown in FIG. 2A, the catheter 12 inserted into the body portion 27 of the sheath 16 remains straight, but when the catheter 12 is further advanced within the sheath 16, the shaft 18 of the catheter 12 is forced by the curved portion 26. Elastically deformed and curved. As a result, the distal end portion of the shaft 18 of the catheter 12 protrudes from the distal end of the sheath 16 in a state of being directed in the same direction (downward) as the outlet direction of the sheath 16 (see FIG. 2B).
 シース16は、操作者が基端側を把持及び操作しながら、生体内の処置対象部位にカテーテル組立体10の先端部を配置でき、且つカテーテル12のシャフト18を湾曲部26で強制的に湾曲させることができるように、適度な剛性を有するものであればよく、例えば、ステンレス鋼、鉄、鉄合金、アルミニウム、アルミニウム合金、チタン、チタン合金等の金属材料、或いは、ポリエチレン、ポリプロピレン、エチレン-酢酸ビニル共重合体等のポリオレフィン、ポリ塩化ビニル、ポリメチルメタクリレート、ポリカーボネート、ポリブタジエン、ポリアミド、ポリエステル等の各種ポリマーにより形成される。 The sheath 16 allows the distal end portion of the catheter assembly 10 to be disposed at a treatment target site in the living body while the operator grasps and operates the proximal end side, and the shaft 18 of the catheter 12 is forcibly bent by the bending portion 26. It is only necessary to have an appropriate rigidity so that it can be made, for example, metal materials such as stainless steel, iron, iron alloy, aluminum, aluminum alloy, titanium, titanium alloy, polyethylene, polypropylene, ethylene- It is formed of various polymers such as polyolefin such as vinyl acetate copolymer, polyvinyl chloride, polymethyl methacrylate, polycarbonate, polybutadiene, polyamide, and polyester.
 図3に示すように、本実施形態におけるシール機構14(隔離膜22及びフレーム24)は、円形に形成されている。なお、シール機構14は、円形に限らず、楕円形、四角形等の形状も採用し得る。処置対象部位の形状は様々であり、処置対象部位の形状に応じて、その形状に適合する形状のシール機構14が取り付けられたカテーテル12を用いることができる。 As shown in FIG. 3, the seal mechanism 14 (the isolation film 22 and the frame 24) in the present embodiment is formed in a circular shape. Note that the sealing mechanism 14 is not limited to a circular shape, and may have an elliptical shape, a rectangular shape, or the like. The shape of the treatment target site is various, and the catheter 12 to which the seal mechanism 14 having a shape suitable for the shape is attached can be used according to the shape of the treatment target site.
 本実施形態に係るカテーテル組立体10は、基本的には以上のように構成されるものであり、以下、その作用及び効果について説明する。以下では、カテーテル組立体10の代表的な用途である関節鏡視下手術での膝関節軟骨損傷部への培養細胞移植を例に挙げて説明する。本例によるカテーテル組立体10の使用方法は、以下の工程(1)~(11)からなる。なお、図4A~図5Cにおいて、符号29は軟骨であり、符号30は軟骨損傷部位であり、符号32は関節鏡であり、符号33は皮膚である。 The catheter assembly 10 according to the present embodiment is basically configured as described above, and the operation and effect thereof will be described below. Hereinafter, a cultured cell transplantation to a knee joint cartilage damaged part in an arthroscopic operation which is a typical use of the catheter assembly 10 will be described as an example. The method of using the catheter assembly 10 according to this example includes the following steps (1) to (11). 4A to 5C, reference numeral 29 is cartilage, reference numeral 30 is a cartilage damage site, reference numeral 32 is an arthroscope, and reference numeral 33 is skin.
 (1) 軟骨損傷部位の郭清
 軟骨損傷部位30が存在する膝関節内に生理食塩水等の液体を注入して作業空間を確保し、膝関節の一方側から郭清器を挿入し、膝関節の他方側から関節鏡32を挿入する。そして、生理食塩水等を洗浄液として用い、関節鏡視下で、膝関節内を洗浄しながら、郭清器により軟骨損傷部位30を郭清(シェービング)し、細胞を移植すべき部位を露見する。その後、郭清器を膝関節から抜去する。
(1) Dissection of the cartilage damage site Inject a liquid such as physiological saline into the knee joint where the cartilage damage site 30 exists to secure a work space, insert a dissection device from one side of the knee joint, The arthroscope 32 is inserted from the other side. Then, using a physiological saline or the like as a cleaning solution, while carving the inside of the knee joint under arthroscopy, the cartilage damaged part 30 is dissected (shaved) with the dissector to reveal the part to be transplanted with cells. Thereafter, the dissector is removed from the knee joint.
 (2) カテーテル組立体の挿入
 関節鏡視下で、郭清器を挿入していた穿刺腔(皮膚切開部)を通じて、シース16内にカテーテル12が挿通され且つシール機構14がシース16内で縮径された状態のカテーテル組立体10を挿入する。
(2) Insertion of catheter assembly The catheter 12 is inserted into the sheath 16 through the puncture cavity (skin incision part) into which the dissection device has been inserted, and the seal mechanism 14 is reduced in diameter within the sheath 16 under arthroscopy. The catheter assembly 10 is inserted.
 (3) 関節内の液体吸引
 カテーテル12の基端部を構成するハブ20(図1参照)に吸引装置(シリンジ等)を接続し、吸引装置及びカテーテル組立体10を用いて膝関節内の液体(洗浄液等)を吸引し、ある程度除去する。図4Aは、膝関節内の液体をある程度除去した後に、少量の液体35が軟骨損傷部位30に残存した状態を示している。なお、膝関節内の液体のある程度の除去は、カテーテル組立体10を用いる代わりに、カテーテル組立体10を膝関節に挿入する前に、シリンジと注射針を用いて行ってもよい。
(3) Liquid suction in the joint A suction device (syringe or the like) is connected to the hub 20 (see FIG. 1) constituting the proximal end portion of the catheter 12, and the liquid in the knee joint is used by using the suction device and the catheter assembly 10. Aspirate (cleaning solution, etc.) and remove to some extent. FIG. 4A shows a state in which a small amount of liquid 35 remains in the cartilage injury site 30 after the liquid in the knee joint has been removed to some extent. In addition, instead of using the catheter assembly 10, some removal of the liquid in the knee joint may be performed using a syringe and an injection needle before inserting the catheter assembly 10 into the knee joint.
 (4) 位置調整
 図4Aに示すように、シース16の先端開口16aが軟骨損傷部位30の真上に来るようにシース16の位置を調整する。
(4) Position Adjustment As shown in FIG. 4A, the position of the sheath 16 is adjusted so that the distal end opening 16 a of the sheath 16 is directly above the cartilage damage site 30.
 (5) シール機構の展開
 カテーテル12をシース16に対して更に押し込むことにより、カテーテル12をシース16内で前進させる。すると、カテーテル12のシャフト18が、シース16の湾曲部26により強制的に曲げられる。そして、カテーテル12を更に押し込むと、シャフト18の先端及びシール機構14が、シース16の先端開口から出る(図4B参照)。この場合、シャフト18が湾曲部26により曲げられているため、シャフト18の先端部はシース16の先端開口16aと同じ方向、すなわち軟骨損傷部位30を指向している。また、シール機構14がシース16の先端開口16aから出た際、フレーム24の弾性復元力により、シール機構14が自己拡張(展開)する。
(5) Deployment of the sealing mechanism The catheter 12 is advanced in the sheath 16 by further pushing the catheter 12 into the sheath 16. Then, the shaft 18 of the catheter 12 is forcibly bent by the bending portion 26 of the sheath 16. When the catheter 12 is further pushed in, the distal end of the shaft 18 and the sealing mechanism 14 come out of the distal end opening of the sheath 16 (see FIG. 4B). In this case, since the shaft 18 is bent by the bending portion 26, the distal end portion of the shaft 18 is directed in the same direction as the distal end opening 16 a of the sheath 16, that is, the cartilage damage site 30. When the seal mechanism 14 exits from the distal end opening 16 a of the sheath 16, the seal mechanism 14 is self-expanded (deployed) by the elastic restoring force of the frame 24.
 (6) 軟骨損傷部位の隔離
 シール機構14を拡張させたら、シール機構14を軟骨損傷部位30の周囲部分の軟骨29に押し当て、シール機構14の下面を軟骨損傷部位30に密着させる。この場合、棒状の押圧デバイス36を用いて、シール機構14に軟骨損傷部位30の周囲を押し当てるとよい(図4C参照)。具体的には、先端にC字状又はU字状の押圧部38と、押圧部38を支持する棒状部40とを有する押圧デバイス36をシース16に挿入し、先端開口16aから突出させた押圧部38を拡張状態のシール機構14の上面に押し当てる。これにより、シール機構14の下面と、軟骨損傷部位30の周囲部分の軟骨29とが密着し、軟骨損傷部位30がその他の組織(正常部)から隔離された状態となる。この結果、その他の組織、すなわち軟骨損傷部位30以外の部分から軟骨損傷部位30内への液体の流入が阻止された状態となる。
(6) Isolation of the cartilage damage site When the seal mechanism 14 is expanded, the seal mechanism 14 is pressed against the cartilage 29 around the cartilage damage site 30 to bring the lower surface of the seal mechanism 14 into close contact with the cartilage damage site 30. In this case, the periphery of the cartilage damage site 30 may be pressed against the seal mechanism 14 using a rod-shaped pressing device 36 (see FIG. 4C). Specifically, a pressing device 36 having a C-shaped or U-shaped pressing portion 38 at the tip and a rod-like portion 40 that supports the pressing portion 38 is inserted into the sheath 16 and pressed from the tip opening 16a. The portion 38 is pressed against the upper surface of the seal mechanism 14 in the expanded state. As a result, the lower surface of the seal mechanism 14 and the cartilage 29 around the cartilage damaged site 30 are in close contact with each other, and the cartilage damaged site 30 is isolated from other tissues (normal portions). As a result, the inflow of the liquid into the cartilage damaged part 30 from other parts, that is, the parts other than the cartilage damaged part 30 is prevented.
 押圧デバイス36の棒状部40は、シール機構14を押し付け易いように、自然状態でシース16と同様に屈曲している。押圧デバイス36は、操作者の手元側からの操作力を先端側に好適に伝達できるように、適度の剛性を有することが好ましく、例えば、上記においてシース16の構成材料として例示したいずれか1つ又は複数の材料から構成され得る。但し、図4Cのようにシース16内に通した押圧デバイス36によりシール機構14を押圧する場合、棒状部40が屈曲した押圧デバイス36をシース16に挿入するためには棒状部40が弾性変形して曲げ角度を小さくする必要があることから、押圧デバイス36にはある程度の可撓性が要求される。なお、シース16内に押圧デバイス36を挿入する代わりに、シース16に別のルーメンを設けておき当該別のルーメンを通して押圧デバイス36を膝関節内に挿入し、シール機構14を押圧してもよい。 The rod-like portion 40 of the pressing device 36 is bent in the same manner as the sheath 16 in a natural state so that the seal mechanism 14 can be easily pressed. The pressing device 36 preferably has an appropriate rigidity so that the operating force from the operator's hand side can be suitably transmitted to the distal end side. For example, any one of the pressing devices 36 exemplified above as the constituent material of the sheath 16 is used. Or it may be composed of a plurality of materials. However, when the sealing mechanism 14 is pressed by the pressing device 36 passed through the sheath 16 as shown in FIG. 4C, the rod-shaped portion 40 is elastically deformed in order to insert the pressing device 36 having the bent rod-shaped portion 40 into the sheath 16. Therefore, the pressing device 36 is required to have a certain degree of flexibility. Instead of inserting the pressing device 36 into the sheath 16, another lumen may be provided in the sheath 16, and the pressing device 36 may be inserted into the knee joint through the other lumen to press the sealing mechanism 14. .
 (7) 軟骨損傷部位の液体吸引
 関節鏡視下で、シール機構14を軟骨損傷部位30の周囲に押し当てることで軟骨損傷部位30とその他の組織との隔離状態を維持したまま、カテーテル12のハブ20に接続された吸引装置を操作して、軟骨損傷部位30上に残存した液体35を完全に除去する(図4D参照)。この場合、隔離膜22は、透明性を有するため、シール機構14により軟骨損傷部位30を覆った状態でも、軟骨損傷部位30内の液体を吸引する様子を関節鏡32により確認することができる。
(7) Liquid Aspiration of Cartilage Damaged Site Under the arthroscopy, the seal mechanism 14 is pressed around the cartilage damaged site 30 to maintain the isolated state of the cartilage damaged site 30 from other tissues. The suction device connected to the hub 20 is operated to completely remove the liquid 35 remaining on the cartilage injury site 30 (see FIG. 4D). In this case, since the isolation film 22 has transparency, even when the cartilage damage site 30 is covered by the seal mechanism 14, it is possible to confirm the state of sucking the liquid in the cartilage damage site 30 with the arthroscope 32.
 なお、シール機構14を軟骨損傷部位30の周囲に押し当てた状態でカテーテル12の先端が液体35に届かない場合には、カテーテル12のルーメン18aに、当該ルーメン18aよりも細径のシャフトを有する別のカテーテル(以下、「吸引用カテーテル」と言う)を挿通させ、当該吸引用カテーテルの先端をカテーテル12の先端から突出させ、当該吸引用カテーテルを介して軟骨損傷部位30上の液体35を吸引してもよい。これにより、カテーテル12の先端から離れた液体35の吸引を確実に実行することができる。 When the distal end of the catheter 12 does not reach the liquid 35 in a state where the seal mechanism 14 is pressed around the cartilage damage site 30, the lumen 18a of the catheter 12 has a shaft having a diameter smaller than that of the lumen 18a. Another catheter (hereinafter referred to as “aspiration catheter”) is inserted, the distal end of the aspiration catheter is protruded from the distal end of the catheter 12, and the liquid 35 on the cartilage injury site 30 is aspirated through the aspiration catheter. May be. Thereby, the suction of the liquid 35 away from the distal end of the catheter 12 can be reliably performed.
 (8) 細胞注入
 軟骨損傷部位30の液体35を完全に除去したら、カテーテル12のハブ20から吸引装置を離脱させ、代わりに、細胞懸濁液42(培養細胞)が充填された注入具(例えば、シリンジ)をハブ20に接続する。上記(7)の工程において上述した吸引カテーテルを用いて液体35の吸引を実施した場合には、カテーテル12のルーメンから吸引カテーテルを抜去した後、カテーテル12のハブ20に注入具を接続する。そして、カテーテル12に接続された注入具を操作して、関節鏡視下で、カテーテル12の先端から細胞懸濁液42を流出させ軟骨損傷部位30に注入する(図5A参照)。隔離膜22は、透明性を有するため、シール機構14により軟骨損傷部位30を覆った状態でも、軟骨損傷部位30に細胞懸濁液42を注入する様子を関節鏡視下で確認することができる。なお、カテーテル12のルーメン18aの内周面又は吸引カテーテルのルーメンの内周面が疎水性を有すると、細胞懸濁液42を損失なく注入できるため、好ましい。
(8) Cell injection When the liquid 35 in the cartilage injury site 30 is completely removed, the suction device is detached from the hub 20 of the catheter 12 and, instead, an injection device filled with the cell suspension 42 (cultured cells) (for example, , Syringe) to the hub 20. When suction of the liquid 35 is performed using the suction catheter described above in step (7), the suction catheter is removed from the lumen of the catheter 12 and then the injection tool is connected to the hub 20 of the catheter 12. Then, by operating the injection tool connected to the catheter 12, the cell suspension 42 is caused to flow out from the distal end of the catheter 12 and injected into the cartilage damage site 30 under arthroscopy (see FIG. 5A). Since the isolation film 22 has transparency, even when the cartilage damage site 30 is covered by the sealing mechanism 14, it is possible to confirm the state in which the cell suspension 42 is injected into the cartilage damage site 30 under an arthroscopic view. . In addition, it is preferable that the inner peripheral surface of the lumen 18a of the catheter 12 or the inner peripheral surface of the lumen of the suction catheter is hydrophobic because the cell suspension 42 can be injected without loss.
 (9) 静置
 軟骨損傷部位30への細胞懸濁液42の注入後、所定時間(例えば、10分間)静置する。上述したように、シール機構14により軟骨損傷部位30とその他の組織とが隔離された状態となっているので、細胞懸濁液42を静置させている間、軟骨損傷部位30以外の部分から軟骨損傷部位30へ液体が流入することがない。
(9) Standing After the cell suspension 42 is injected into the cartilage injury site 30, the plate is allowed to stand for a predetermined time (for example, 10 minutes). As described above, since the cartilage damage site 30 and other tissues are isolated from each other by the seal mechanism 14, while the cell suspension 42 is allowed to stand still, the part other than the cartilage damage site 30 is used. The liquid does not flow into the cartilage damage site 30.
 (10) 隔離解除及びシール機構の収容
 上記所定時間が経過したら、カテーテル12を基端側へ移動操作して、シール機構14を持ち上げ、軟骨損傷部位30の周囲から離脱させる(図5B参照)。これにより、シール機構14による隔離が解除される。その後、シース16に対してカテーテル12を更に基端側に移動させると、シール機構14がシース16の内周面による規制を受けて収縮し、シース16内に収容される(図5C参照)。
(10) Release of isolation and accommodation of sealing mechanism When the predetermined time has elapsed, the catheter 12 is moved to the proximal end side to lift the sealing mechanism 14 and disengage from the periphery of the cartilage damage site 30 (see FIG. 5B). Thereby, the isolation | separation by the sealing mechanism 14 is cancelled | released. Thereafter, when the catheter 12 is further moved to the proximal end side with respect to the sheath 16, the seal mechanism 14 is contracted by being restricted by the inner peripheral surface of the sheath 16 and is accommodated in the sheath 16 (see FIG. 5C).
 (11) カテーテル組立体及び関節鏡の抜去
 その後、シース16内にシール機構14が収容された状態のカテーテル組立体10と関節鏡32を膝関節から抜去する。
(11) Removal of catheter assembly and arthroscope Thereafter, the catheter assembly 10 and the arthroscope 32 in a state where the seal mechanism 14 is accommodated in the sheath 16 are removed from the knee joint.
 以上の工程(1)~(11)により、培養細胞の軟骨損傷部位30への移植が完了する。 Through the above steps (1) to (11), transplantation of the cultured cells to the cartilage damage site 30 is completed.
 以上の説明から了解されるように、本実施形態に係るカテーテル組立体10を用いれば、次のような細胞移植方法を実施することができる。すなわち、当該細胞移植方法は、
 中空状のシャフト18と、当該シャフト18の先端部近傍に設けられた収縮及び拡張可能なシール機構14と、当該シール機構14を収容可能なシース16とを備えたカテーテル組立体10を用意する工程と、
 前記シール機構14が前記シース16に収容された状態のカテーテル組立体10を、処置対象部位が存在する生体内に挿入する工程と、
 前記シース16内から前記シール機構14を出して前記シール機構14を拡張させる工程と、
 拡張した前記シール機構14を前記処置対象部位の周囲に押し当てることにより、前記処置対象部位とその他の組織とを隔離する工程と、
 前記カテーテル12を介して、前記処置対象部位上に残存する液体を吸引する工程と、
 前記カテーテル12を介して、前記処置対象部位へ細胞(培養細胞)を注入する工程とを含む、ことを特徴とする。
As will be understood from the above description, the following cell transplantation method can be performed by using the catheter assembly 10 according to the present embodiment. That is, the cell transplantation method is:
A step of preparing a catheter assembly 10 including a hollow shaft 18, a contractible and expandable seal mechanism 14 provided in the vicinity of the distal end portion of the shaft 18, and a sheath 16 that can accommodate the seal mechanism 14. When,
Inserting the catheter assembly 10 in a state where the seal mechanism 14 is accommodated in the sheath 16 into a living body where a treatment target site exists;
Extending the seal mechanism 14 out of the sheath 16 and expanding the seal mechanism 14;
Isolating the treatment target site from other tissues by pressing the expanded seal mechanism 14 around the treatment target site;
Sucking the liquid remaining on the treatment target site through the catheter 12;
And a step of injecting cells (cultured cells) into the treatment target site through the catheter 12.
 以上説明したように、本実施形態に係るカテーテル組立体10によれば、生体外からの簡易な操作によって、生体内でシール機構14を拡張させ、拡張させたシール機構14を処置対象部位の周囲に押し当てることにより、処置対象部位をその他の組織から隔離し、これにより処置対象部位への液体の流入を阻止することができる。よって、処置対象部位に対する治療を、当該治療効果を低減することなく、簡易且つ確実に行うことができる。 As described above, according to the catheter assembly 10 according to the present embodiment, the seal mechanism 14 is expanded in vivo by a simple operation from outside the living body, and the expanded seal mechanism 14 is disposed around the treatment target site. By pressing against the treatment target region, the treatment target region can be isolated from other tissues, thereby preventing liquid from flowing into the treatment target region. Therefore, the treatment for the treatment target site can be performed easily and reliably without reducing the therapeutic effect.
 本実施形態の場合、前記シール機構14は、その内周部が前記シャフト18の外周に接合された隔離膜22と、隔離膜22を支持するフレーム24とを有するので、処置対象部位の周囲に対するシール機構14の密着性を向上でき、処置対象部位の外側から内側への液体の浸入を一層好適に防止できる。 In the case of the present embodiment, the seal mechanism 14 includes an isolation film 22 whose inner periphery is joined to the outer periphery of the shaft 18 and a frame 24 that supports the isolation film 22. The adhesion of the seal mechanism 14 can be improved, and the penetration of the liquid from the outside to the inside of the treatment target site can be more preferably prevented.
 また、本実施形態の場合、フレーム24は隔離膜22の外周縁部に設けられたリング状の可撓性を有する部材であり、シール機構14は、シース16から出た際にフレーム24の弾性復元力により自己拡張する。すなわち、シース16に対してカテーテル12を先端方向に移動させるシール機構14が自動で拡張する。このため、別途の拡張操作を要することなく、単一の操作でシール機構14を拡張させることができ、操作性に優れる。 In the case of this embodiment, the frame 24 is a ring-shaped flexible member provided on the outer peripheral edge of the isolation film 22, and the seal mechanism 14 is elastic when it comes out of the sheath 16. Self-expand by resilience. That is, the seal mechanism 14 that moves the catheter 12 in the distal direction relative to the sheath 16 is automatically expanded. For this reason, the seal mechanism 14 can be expanded by a single operation without requiring a separate expansion operation, and the operability is excellent.
[第2実施形態]
 図6は、本発明の第2実施形態に係るカテーテル組立体10aの一部省略斜視図である。なお、第2実施形態に係るカテーテル組立体10aにおいて、第1実施形態に係るカテーテル組立体10と同一又は同様な機能及び効果を奏する要素には同一の参照符号を付し、詳細な説明を省略する。
[Second Embodiment]
FIG. 6 is a partially omitted perspective view of the catheter assembly 10a according to the second embodiment of the present invention. In the catheter assembly 10a according to the second embodiment, elements having the same or similar functions and effects as those of the catheter assembly 10 according to the first embodiment are denoted by the same reference numerals, and detailed description thereof is omitted. To do.
 第2実施形態に係るカテーテル組立体10aは、シール機構50の構成において、第1実施形態に係るカテーテル組立体10と異なる。ここで、図7Aは、シール機構50の収縮状態での縦断面図であり、図7Bは、シール機構50の拡張状態での縦断面図である。図8は、シール機構50の拡張状態での斜視図である。図6~図8に示すように、シール機構50は、シャフト18の外周に接合された隔離膜52と、隔離膜52を支持する複数のフレーム54と、当該複数のフレーム54が連結されシャフト18に対して摺動可能な連結部材56とを備える。 The catheter assembly 10a according to the second embodiment is different from the catheter assembly 10 according to the first embodiment in the configuration of the seal mechanism 50. Here, FIG. 7A is a longitudinal sectional view of the sealing mechanism 50 in a contracted state, and FIG. 7B is a longitudinal sectional view of the sealing mechanism 50 in an expanded state. FIG. 8 is a perspective view of the seal mechanism 50 in an expanded state. As shown in FIGS. 6 to 8, the seal mechanism 50 includes a separation film 52 joined to the outer periphery of the shaft 18, a plurality of frames 54 that support the separation film 52, and the plurality of frames 54 connected to the shaft 18. And a slidable connecting member 56.
 シール機構50の隔離膜52は、第1実施形態における隔離膜22と同様に構成されている。フレーム54は、シャフト18の周囲に複数(図示例では、8本)設けられ、シール機構50の拡張時に放射状に展開する(図7B、図8参照)。具体的には、フレーム54は、一端部が連結部材56に回動可能に連結され、他端部が隔離膜52の外周縁部に連結されている。フレーム54は、隔離膜52を確実に展開させることができるように、適度の剛性を有することが好ましく、例えば、第1実施形態におけるフレーム54と同様の材料により構成し得る。 The isolation film 52 of the seal mechanism 50 is configured in the same manner as the isolation film 22 in the first embodiment. A plurality of the frames 54 are provided around the shaft 18 (eight in the illustrated example), and expand radially when the seal mechanism 50 is expanded (see FIGS. 7B and 8). Specifically, one end of the frame 54 is rotatably connected to the connecting member 56, and the other end is connected to the outer peripheral edge of the isolation film 52. The frame 54 preferably has an appropriate rigidity so that the isolation film 52 can be reliably deployed. For example, the frame 54 can be made of the same material as the frame 54 in the first embodiment.
 連結部材56は、リング状に形成され、そのリング状の内側にシャフト18が挿通されており、シャフト18に沿って変位可能である。連結部材56の外周部には、上述したフレーム54が回動可能に連結されている。シャフト18の外周部において隔離膜52とシャフト18との連結部分の近傍であって隔離膜52よりもシャフト18の基端側の箇所には、隔離膜52が展開するとともに複数のフレーム54が放射状に展開した状態となる位置に連結部材56が変位したときに、連結部材56に係合することにより連結部材56の基端方向への移動を阻止(規制)するロック部60が設けられている。ロック部60は、例えば、弾性体からなり、シャフト18の先端方向に向かってシャフト18の外周面からの距離(高さ)が大きくなるように傾斜するテーパ面を有する。 The connecting member 56 is formed in a ring shape, and the shaft 18 is inserted inside the ring shape and can be displaced along the shaft 18. The frame 54 described above is rotatably connected to the outer peripheral portion of the connecting member 56. In the outer peripheral portion of the shaft 18, in the vicinity of the connecting portion between the isolation film 52 and the shaft 18, the isolation film 52 expands and a plurality of frames 54 radiate at a position closer to the proximal end of the shaft 18 than the isolation film 52. When the connecting member 56 is displaced to a position where the connecting member 56 is deployed, a lock portion 60 is provided that engages the connecting member 56 to prevent (restrict) movement of the connecting member 56 in the proximal direction. . The lock portion 60 is made of, for example, an elastic body and has a tapered surface that is inclined so that the distance (height) from the outer peripheral surface of the shaft 18 increases toward the distal end of the shaft 18.
 シール機構50が収縮した状態(図7Aの状態)では、連結部材56は、ロック部60からシャフト18の基端方向に離れた位置にある。シール機構50を拡張(展開)させる際に、連結部材56がシャフト18の基端方向に移動していくと、やがて連結部材56はロック部60を乗り越えてロック部60よりもシャフト18の先端側(ロック部60と隔離膜52との間)まで変位する(図7B参照)。連結部材56がロック部60を乗り越えるとき、ロック部60が弾性圧縮変形するが、連結部材56がロック部60を乗り越えた後は、ロック部60は元の形状に復元する。このため、連結部材56はロック部60の先端側の端面により係止され、連結部材56がシャフト18の基端方向へ移動することが阻止されたロック状態となる。 In the state where the seal mechanism 50 is contracted (the state shown in FIG. 7A), the connecting member 56 is located away from the lock portion 60 in the proximal direction of the shaft 18. When the connecting member 56 moves in the proximal direction of the shaft 18 when the seal mechanism 50 is expanded (deployed), the connecting member 56 eventually gets over the lock portion 60 and is closer to the distal end side of the shaft 18 than the lock portion 60. Displaces up to (between the lock portion 60 and the isolation film 52) (see FIG. 7B). When the connecting member 56 gets over the lock part 60, the lock part 60 is elastically compressed and deformed. However, after the connecting member 56 gets over the lock part 60, the lock part 60 is restored to its original shape. For this reason, the connecting member 56 is locked by the end surface on the distal end side of the lock portion 60, and the connecting member 56 is in a locked state in which the connecting member 56 is prevented from moving in the proximal direction of the shaft 18.
 本実施形態に係るカテーテル組立体10aは、基本的には以上のように構成されるものであり、以下、その作用及び効果について説明する。以下では、図9A~図10Dを参照し、カテーテル組立体10aの代表的な用途である関節鏡視下手術での膝関節軟骨損傷部への培養細胞移植を例に挙げて説明する。本例によるカテーテル組立体10aの使用方法は、以下の工程(1a)~(11a)からなる。 The catheter assembly 10a according to the present embodiment is basically configured as described above, and the operation and effect thereof will be described below. In the following, referring to FIGS. 9A to 10D, an example of cultured cell transplantation into a knee joint cartilage injury site in arthroscopic surgery, which is a typical use of the catheter assembly 10a, will be described. The method of using the catheter assembly 10a according to this example includes the following steps (1a) to (11a).
 (1a) 軟骨損傷部位の郭清
 第1実施形態における上記(1)と同様に、郭清器により軟骨損傷部位30を郭清し、その後、郭清器を膝関節から抜去する。
(1a) Dissection of cartilage damage site As in the case of (1) in the first embodiment, the cartilage damage site 30 is dissected with a dissector, and then the dissector is removed from the knee joint.
 (2a) カテーテル組立体の挿入
 関節鏡視下で、郭清器を挿入していた穿刺腔(皮膚切開部)を通じて、シース16内にカテーテル12が挿通され且つシール機構50がシース16内で縮径された状態のカテーテル組立体10aを挿入する。
(2a) Insertion of catheter assembly The catheter 12 is inserted into the sheath 16 through the puncture cavity (skin incision portion) into which the dissection device has been inserted under the arthroscopy, and the seal mechanism 50 is reduced in diameter in the sheath 16. The catheter assembly 10a is inserted.
 (3a) 関節内の液体吸引
 カテーテル12の基端部を構成するハブ20に吸引装置(シリンジ等)を接続し、吸引装置及びカテーテル組立体10aを用いて膝関節内の液体(洗浄液等)を吸引し、ある程度除去する。図9Aは、膝関節内の液体をある程度除去した後に、少量の液体35が軟骨損傷部位30に残存した状態を示している。なお、膝関節内の液体のある程度の除去は、カテーテル組立体10aを用いる代わりに、カテーテル組立体10aを膝関節に挿入する前に、シリンジと注射針を用いて行ってもよい。
(3a) Liquid suction in the joint A suction device (syringe or the like) is connected to the hub 20 constituting the proximal end portion of the catheter 12, and the liquid in the knee joint (cleaning fluid or the like) is discharged using the suction device and the catheter assembly 10a. Aspirate and remove to some extent. FIG. 9A shows a state in which a small amount of liquid 35 remains in the cartilage injury site 30 after the liquid in the knee joint has been removed to some extent. It should be noted that some removal of the liquid in the knee joint may be performed using a syringe and an injection needle before inserting the catheter assembly 10a into the knee joint, instead of using the catheter assembly 10a.
 (4a) 位置調整
 図9Aに示すように、シース16の先端開口16aが軟骨損傷部位30の真上に来るようにシース16の位置を調整する。
(4a) Position Adjustment As shown in FIG. 9A, the position of the sheath 16 is adjusted so that the distal end opening 16 a of the sheath 16 is directly above the cartilage damage site 30.
 (5a) シール機構の展開
 カテーテル12をシース16に対して更に押し込むことにより、カテーテル12をシース16内で前進させる。すると、カテーテル12のシャフト18が、シース16の湾曲部26により強制的に曲げられる。そして、カテーテル12を更に押し込むと、シャフト18の先端及びシール機構50が、シース16の先端開口から出る(図9B参照)。この場合、シャフト18が湾曲部26により曲げられているため、シャフト18の先端部はシース16の先端開口16aと同じ方向、すなわち軟骨損傷部位30を指向する。次に、押圧デバイス36をシース16に挿入し、押圧デバイス36の先端に設けられた押圧部38で連結部材56又はフレーム54を下方に押し込み、連結部材56がロック部60を乗り越えてロック部60に係止される位置まで、連結部材56をシャフト18の先端方向に変位させる(図9C参照)。この際、複数のフレーム54が放射状に広がることに伴って隔離膜52が展開させられ、図9Cに示すようにシール機構50が拡張するに至る。なお、シース16内に押圧デバイス36を挿入する代わりに、シース16に別のルーメンを設けておき当該別のルーメンを通して押圧デバイス36を膝関節内に挿入し、シール機構50を拡張させる上記の操作を行ってもよい。
(5a) Deployment of seal mechanism The catheter 12 is advanced in the sheath 16 by further pushing the catheter 12 into the sheath 16. Then, the shaft 18 of the catheter 12 is forcibly bent by the bending portion 26 of the sheath 16. When the catheter 12 is further pushed in, the distal end of the shaft 18 and the sealing mechanism 50 come out from the distal end opening of the sheath 16 (see FIG. 9B). In this case, since the shaft 18 is bent by the bending portion 26, the distal end portion of the shaft 18 is directed in the same direction as the distal end opening 16 a of the sheath 16, that is, the cartilage damage site 30. Next, the pressing device 36 is inserted into the sheath 16, and the connecting member 56 or the frame 54 is pushed downward by the pressing portion 38 provided at the distal end of the pressing device 36, and the connecting member 56 gets over the lock portion 60 and locks 60. The connecting member 56 is displaced in the direction of the distal end of the shaft 18 until it is locked to the position (see FIG. 9C). At this time, as the plurality of frames 54 spread radially, the isolation film 52 is expanded, and the seal mechanism 50 is expanded as shown in FIG. 9C. Instead of inserting the pressing device 36 into the sheath 16, the above-described operation of providing another lumen in the sheath 16, inserting the pressing device 36 into the knee joint through the other lumen, and expanding the seal mechanism 50. May be performed.
 (6a) 軟骨損傷部位の隔離
 シール機構50を拡張させたら、シール機構50を軟骨損傷部位30の周囲に押し当て、シール機構50の下面を軟骨損傷部位30の周囲に密着させる。この場合、図9Dのように押圧デバイス36を用いてシール機構50を軟骨損傷部位30に押し当てると、シール機構50の下面と軟骨損傷部位30の周囲部分との密着性を一層向上させることができる(図9D参照)。これにより、軟骨損傷部位30がその他の組織(正常部)から隔離され、その他の組織から軟骨損傷部位30内への液体の流入が阻止された状態となる。
(6a) Isolation of the cartilage damage site When the seal mechanism 50 is expanded, the seal mechanism 50 is pressed around the cartilage damage site 30 and the lower surface of the seal mechanism 50 is brought into close contact with the cartilage damage site 30. In this case, when the sealing mechanism 50 is pressed against the cartilage damaged site 30 using the pressing device 36 as shown in FIG. 9D, the adhesion between the lower surface of the sealing mechanism 50 and the surrounding portion of the cartilage damaged site 30 can be further improved. Yes (see FIG. 9D). As a result, the cartilage damage site 30 is isolated from other tissues (normal parts), and the inflow of liquid from the other tissues into the cartilage damage site 30 is prevented.
 (7a) 軟骨損傷部位の液体吸引
 関節鏡視下で、シール機構50を軟骨損傷部位30の周囲に押し当てることで軟骨損傷部位30とその他の組織との隔離状態を維持したまま、カテーテル12のハブ20に接続された吸引装置を操作して、軟骨損傷部位30上に残存した液体35を完全に除去する(図10A参照)。なお、シール機構50を軟骨損傷部位30の周囲に押し当てた状態でカテーテル12の先端が液体35に接触しない場合には、第1実施形態における(7)の工程と同様に、カテーテル12のルーメン18aに、吸引用カテーテルを挿通させ、当該吸引用カテーテルの先端をカテーテル12の先端から突出させ、当該吸引用カテーテルを介して軟骨損傷部位30上の液体35を吸引してもよい。これにより、カテーテル12の先端から離れた液体35の吸引を確実に実行することができる。
(7a) Liquid suction of the cartilage damage site Under the arthroscopic view, the seal mechanism 50 is pressed around the cartilage damage site 30 to maintain the isolated state between the cartilage damage site 30 and other tissues. The suction device connected to the hub 20 is operated to completely remove the liquid 35 remaining on the cartilage damage site 30 (see FIG. 10A). In the case where the distal end of the catheter 12 does not contact the liquid 35 with the sealing mechanism 50 pressed around the cartilage damage site 30, the lumen of the catheter 12 is the same as in the step (7) in the first embodiment. The suction catheter may be inserted into 18a, the tip of the suction catheter may protrude from the tip of the catheter 12, and the liquid 35 on the cartilage injury site 30 may be sucked through the suction catheter. Thereby, the suction of the liquid 35 away from the distal end of the catheter 12 can be reliably performed.
 (8a) 細胞注入
 軟骨損傷部位30の液体を完全に除去したら、カテーテル12のハブ20から吸引装置を離脱させ、代わりに、細胞懸濁液42が充填された注入具(例えば、シリンジ)をハブ20に接続する。上記(7a)の工程において上述した吸引カテーテルを用いて液体35の吸引を実施した場合には、カテーテル12のルーメンから吸引カテーテルを抜去した後、カテーテル12のハブ20に注入具を接続する。そして、カテーテル12に接続された注入具を操作して、関節鏡視下で、カテーテル12の先端から細胞懸濁液42を流出させ軟骨損傷部位30に注入する(図10B参照)。
(8a) Cell Injection When the liquid in the cartilage injury site 30 is completely removed, the suction device is detached from the hub 20 of the catheter 12, and instead, an injection tool (for example, a syringe) filled with the cell suspension 42 is used as the hub. 20 is connected. When suction of the liquid 35 is performed using the suction catheter described above in the step (7a), the suction catheter is removed from the lumen of the catheter 12 and then the injection tool is connected to the hub 20 of the catheter 12. Then, by operating the injection tool connected to the catheter 12, the cell suspension 42 flows out from the distal end of the catheter 12 and is injected into the cartilage damage site 30 under arthroscopy (see FIG. 10B).
 (9a) 静置
 軟骨損傷部位30への細胞懸濁液42の注入後、所定時間(例えば、10分間)静置する。上述したように、シール機構50により軟骨損傷部位30とその他の組織とが隔離された状態となっているので、細胞懸濁液42を静置させている間、軟骨損傷部位30以外の部分から軟骨損傷部位30へ液体が流入することがない。
(9a) Standing After the cell suspension 42 is injected into the cartilage injury site 30, the plate is left standing for a predetermined time (for example, 10 minutes). As described above, since the cartilage damage site 30 and other tissues are isolated by the seal mechanism 50, while the cell suspension 42 is allowed to stand still, the part other than the cartilage damage site 30 is used. The liquid does not flow into the cartilage damage site 30.
 (10a) 隔離解除及びシール機構の収容
 上記所定時間が経過したら、カテーテル12を基端側へ移動操作して、シール機構50を持ち上げ、軟骨損傷部位30の周囲から離脱させる。これにより、シール機構50による隔離が解除される。その後、押圧デバイス36の押圧部38をロック部60に接触させ、押圧部38でロック部60を弾性変形させることにより、ロック部60による連結部材56の係止を解除する。ロック部60による係止が解除されると連結部材56はシャフト18の基端方向に移動可能となる。次に、押圧部38を連結部材56又はフレーム54に引っ掛けて連結部材56をシャフト18の基端側に移動させることにより、図10Cのようにシール機構50を収縮させる。シール機構50を収縮させたら、シース16に対してカテーテル12を更に基端側に移動させ、シール機構50をシース16内に収容する(図10D参照)。
(10a) Isolation release and accommodation of sealing mechanism When the predetermined time has elapsed, the catheter 12 is moved to the proximal end side to lift the sealing mechanism 50 and disengage it from the periphery of the cartilage damage site 30. Thereby, the isolation | separation by the seal mechanism 50 is cancelled | released. Thereafter, the pressing portion 38 of the pressing device 36 is brought into contact with the lock portion 60, and the locking portion 60 is elastically deformed by the pressing portion 38, thereby releasing the locking of the connecting member 56 by the locking portion 60. When the locking by the lock portion 60 is released, the connecting member 56 can move in the proximal direction of the shaft 18. Next, the sealing portion 50 is contracted as shown in FIG. 10C by hooking the pressing portion 38 on the connecting member 56 or the frame 54 and moving the connecting member 56 to the proximal end side of the shaft 18. When the sealing mechanism 50 is contracted, the catheter 12 is further moved to the proximal end side with respect to the sheath 16, and the sealing mechanism 50 is accommodated in the sheath 16 (see FIG. 10D).
 (11a) カテーテル組立体及び関節鏡の抜去
 その後、シース16内にシール機構50が収容された状態のカテーテル組立体10aと関節鏡32を膝関節から抜去する。
(11a) Removal of catheter assembly and arthroscope Thereafter, the catheter assembly 10a and the arthroscope 32 in a state where the seal mechanism 50 is accommodated in the sheath 16 are removed from the knee joint.
 以上の工程(1a)~(11a)により、培養細胞の軟骨損傷部位30への移植が完了する。 Through the above steps (1a) to (11a), the transplantation of the cultured cells to the cartilage damage site 30 is completed.
 以上の説明から了解されるように、本実施形態に係るカテーテル組立体10aを用いれば、次のような細胞移植方法を実施することができる。すなわち、当該細胞移植方法は、
 中空状のシャフト18と、当該シャフト18の先端部近傍に設けられた収縮及び拡張可能なシール機構50と、当該シール機構50を収容可能なシース16とを備えたカテーテル組立体10aを用意する工程と、
 前記シール機構50が前記シース16に収容された状態のカテーテル組立体10aを、処置対象部位が存在する生体内に挿入する工程と、
 前記シース16内から前記シール機構50を出して前記シール機構50を拡張させる工程と、
 拡張した前記シール機構50を前記処置対象部位の周囲に押し当てることにより、前記処置対象部位とその他の組織とを隔離する工程と、
 前記カテーテル12を介して、前記処置対象部位上に残存する液体を吸引する工程と、
 前記カテーテル12を介して、前記処置対象部位へ細胞(培養細胞)を注入する工程とを含む、ことを特徴とする。
As can be understood from the above description, the following cell transplantation method can be performed by using the catheter assembly 10a according to the present embodiment. That is, the cell transplantation method is:
A step of preparing a catheter assembly 10 a including a hollow shaft 18, a contractible and expandable seal mechanism 50 provided in the vicinity of the tip of the shaft 18, and a sheath 16 that can accommodate the seal mechanism 50. When,
Inserting the catheter assembly 10a in a state where the seal mechanism 50 is accommodated in the sheath 16 into a living body where a treatment target site exists;
Extending the seal mechanism 50 out of the sheath 16 to expand the seal mechanism 50;
Isolating the treatment target site from other tissues by pressing the expanded seal mechanism 50 around the treatment target site;
Sucking the liquid remaining on the treatment target site through the catheter 12;
And a step of injecting cells (cultured cells) into the treatment target site through the catheter 12.
 以上説明したように、本実施形態に係るカテーテル組立体10aによれば、フレーム54が前記シャフト18の周囲に複数設けられ、シール機構50の拡張時に放射状に展開するので、拡張時におけるシール機構50全体の剛性を高めることができ、シール機構50と処置対象部位の周囲との密着性を効果的に高めることができる。 As described above, according to the catheter assembly 10a according to the present embodiment, a plurality of frames 54 are provided around the shaft 18 and expand radially when the seal mechanism 50 is expanded. The overall rigidity can be increased, and the adhesion between the seal mechanism 50 and the periphery of the treatment target site can be effectively increased.
 また、本実施形態の場合、シール機構50は、前記複数のフレーム54に連結されシャフト18に沿って変位可能な連結部材56を備えるので、複数のフレーム54をバランスよく放射状に展開させることができる。このため、シール機構50と処置対象部位の周囲との密着性を効果的に高めることができる。 Further, in the case of the present embodiment, the seal mechanism 50 includes the connecting member 56 that is connected to the plurality of frames 54 and can be displaced along the shaft 18, so that the plurality of frames 54 can be radially developed with good balance. . For this reason, the adhesiveness of the seal mechanism 50 and the circumference | surroundings of a treatment object site | part can be improved effectively.
 さらに、本実施形態の場合、前記シャフト18の外周部に、連結部材56を解除可能に係止するロック部60が設けられるので、ロック部60による連結部材56の移動規制を解除する操作をしない限り、シール機構50の拡張状態を確実に維持できる。 Furthermore, in the case of this embodiment, since the lock part 60 which latches the connection member 56 releasably is provided in the outer peripheral part of the said shaft 18, operation which cancels | releases the movement restriction | limiting of the connection member 56 by the lock part 60 is not performed. As long as the expansion state of the seal mechanism 50 can be reliably maintained.
 なお、第2実施形態において、第1実施形態と共通する各構成部分については、第1実施形態における当該共通の各構成部分がもたらす作用及び効果と同一又は同様の作用及び効果が得られることは勿論である。 In addition, in the second embodiment, for each component common to the first embodiment, it is possible to obtain the same or similar operation and effect as the operation and effect brought about by the common component in the first embodiment. Of course.
[その他の変形例]
 図11Aに示す変形例に係るシール機構70のように、隔離膜52の下面(処置対象部位に接触する側の面)に、環状のシール部材72を設けてもよい。シール部材72は、例えば、Oリングにより構成され、隔離膜22の下面の外周縁部に沿って配置されている。このようなシール部材72を設けることにより、シール機構70を処置対象部位の周囲に押し付けた際のシール機構70と処置対象部位の周囲との間のシール性を高めることができ、処置対象部位への液体の流入を一層確実に阻止することができる。
[Other variations]
As in the seal mechanism 70 according to the modification shown in FIG. 11A, an annular seal member 72 may be provided on the lower surface of the isolation film 52 (the surface on the side in contact with the treatment target site). The seal member 72 is configured by, for example, an O-ring, and is disposed along the outer peripheral edge portion of the lower surface of the isolation film 22. By providing such a seal member 72, it is possible to improve the sealing performance between the seal mechanism 70 and the periphery of the treatment target site when the seal mechanism 70 is pressed around the treatment target site. Inflow of the liquid can be more reliably prevented.
 なお、シール部材72に代えて、柔軟性を有する環状の多孔質体を隔離膜22の下面の外周縁部に設けてもよい。このような多孔質体を設けた構成の場合、当該多孔質体が、処置対象部位の周囲の表面形状(凹凸形状等)に追従するように弾性変形することで、処置対象部位の周囲によく密着するため、シール機構70と処置対象部位との間のシール性を高めることができる。 In addition, instead of the seal member 72, a flexible annular porous body may be provided on the outer peripheral edge of the lower surface of the isolation film 22. In the case of a configuration in which such a porous body is provided, the porous body can be elastically deformed so as to follow the surface shape (uneven shape, etc.) around the treatment target site, so that it can be well around the treatment target site. Since it adheres closely, the sealing performance between the sealing mechanism 70 and a treatment object site | part can be improved.
 図11Bに示す変形例に係るシャフト80のように、液体吸引及び細胞注入のためのルーメン81の他に、撮像手段(細径のカメラ)を挿入可能な撮像用ルーメン82と、光照射手段(光源に接続された光ファイバー等)を挿入可能な照明用ルーメン83とを設けてもよい。このような構成のシャフト80によれば、内視鏡又は関節鏡を使用しない場合でも、撮像用ルーメン82に撮像手段を挿入するとともに、照明用ルーメン83に光照射手段を挿入することにより、カテーテル組立体10、10aを確実に処置対象部位に配置することができる。また、シール機構14、50、70により処置対象部位を覆った状態においても、処置対象部位内を直接観察することができるため、処置対象部位内の液体を完全に除去したことを確認したうえで細胞注入を実施することができ、確実に治療を行うことができる。図11Bに示す構成の場合、隔離膜22の下面(処置対象部位に接触する側の面)は、光を反射し易いように、例えば、鏡面、白色等で構成されるとよい。 Like the shaft 80 according to the modification shown in FIG. 11B, in addition to the lumen 81 for liquid suction and cell injection, an imaging lumen 82 into which an imaging means (a small-diameter camera) can be inserted, and a light irradiation means ( An illumination lumen 83 into which an optical fiber or the like connected to a light source can be inserted may be provided. According to the shaft 80 having such a configuration, even when an endoscope or an arthroscope is not used, the imaging means is inserted into the imaging lumen 82 and the light irradiation means is inserted into the illumination lumen 83, whereby the catheter The assemblies 10 and 10a can be reliably disposed at the treatment target site. In addition, since the inside of the treatment target site can be directly observed even in the state where the treatment target site is covered by the sealing mechanisms 14, 50, 70, it is confirmed that the liquid in the treatment target site has been completely removed. Cell injection can be performed and treatment can be reliably performed. In the case of the configuration illustrated in FIG. 11B, the lower surface of the isolation film 22 (the surface on the side in contact with the treatment target site) may be configured with, for example, a mirror surface or white so as to easily reflect light.
 上記において、本発明について好適な実施形態を挙げて説明したが、本発明は前記実施形態に限定されるものではなく、本発明の要旨を逸脱しない範囲において、種々の改変が可能なことは言うまでもない。例えば、上記実施形態ではカテーテル組立体10、10aの用途として膝関節での関節鏡視下細胞移植手術を挙げたが、本発明はこれに限定されるものではない。すなわち、本発明に係るカテーテル組立体10、10aは、液体を排出することを伴う手術方法であればいかなるものにも適用することができる。例えば、本発明に係るカテーテル組立体10、10aは、脳内、腹腔内、手根管、肩関節、肘関節、脊椎等の内視鏡手術や胸水、腹水の水抜に使用することができる。 In the above description, the present invention has been described with reference to preferred embodiments. However, the present invention is not limited to the above-described embodiments, and various modifications can be made without departing from the scope of the present invention. Yes. For example, in the above-described embodiment, an arthroscopic cell transplantation operation at the knee joint is given as an application of the catheter assembly 10, 10a, but the present invention is not limited to this. That is, the catheter assembly 10, 10a according to the present invention can be applied to any surgical method that involves draining a liquid. For example, the catheter assemblies 10 and 10a according to the present invention can be used for endoscopic surgery such as intracerebral, intraperitoneal, carpal tunnel, shoulder joint, elbow joint, spine, etc., and drainage of pleural effusion and ascites.

Claims (13)

  1.  ルーメン(18a、81)を有する中空状のシャフト(18、80)と、
     前記シャフト(18、80)の先端部近傍の外周に設けられ、収縮及び拡張が可能なシール機構(14、50、70)と、
     前記シャフト(18、80)が挿通可能であるとともに、収縮状態の前記シール機構(14、50、70)を収容可能なシース(16)とを備え、
     生体内で、拡張した前記シール機構(14、50、70)が処置対象部位の周囲に押圧されたとき、前記処置対象部位の内側と外側とを前記シール機構(14、50、70)により隔離するように構成されている、
     ことを特徴とするカテーテル組立体(10、10a)。
    A hollow shaft (18, 80) having a lumen (18a, 81);
    A seal mechanism (14, 50, 70) provided on the outer periphery in the vicinity of the tip of the shaft (18, 80) and capable of contraction and expansion;
    The shaft (18, 80) can be inserted, and the sheath (16) can accommodate the contracted seal mechanism (14, 50, 70).
    In vivo, when the expanded seal mechanism (14, 50, 70) is pressed around the treatment target site, the inside and the outside of the treatment target site are isolated by the seal mechanism (14, 50, 70). Is configured to
    A catheter assembly (10, 10a) characterized in that.
  2.  請求項1記載のカテーテル組立体(10、10a)において、
     前記シール機構(14、50、70)は、前記シャフト(18、80)の外周に接合された隔離膜(22、52)と、前記隔離膜(22、52)を支持するフレーム(24、54)とを有する、
     ことを特徴とするカテーテル組立体(10、10a)。
    The catheter assembly (10, 10a) according to claim 1,
    The sealing mechanism (14, 50, 70) includes a separation membrane (22, 52) joined to an outer periphery of the shaft (18, 80), and a frame (24, 54) that supports the separation membrane (22, 52). )
    A catheter assembly (10, 10a) characterized in that.
  3.  請求項2記載のカテーテル組立体(10)において、
     前記フレーム(24)は、前記隔離膜(22)の外周縁部に設けられたリング状の可撓性を有する部材であり、
     前記シール機構(14)は、前記シース(16)から出た際に、前記フレーム(24)の弾性復元力により自己拡張する、
     ことを特徴とするカテーテル組立体(10)。
    Catheter assembly (10) according to claim 2,
    The frame (24) is a ring-shaped flexible member provided on the outer peripheral edge of the isolation film (22),
    The sealing mechanism (14) self-expands by the elastic restoring force of the frame (24) when exiting from the sheath (16).
    A catheter assembly (10) characterized in that.
  4.  請求項2記載のカテーテル組立体(10a)において、
     前記フレーム(54)は、前記シャフト(18)の周囲に複数設けられ、前記シール機構(50)の拡張時に放射状に展開する、
     ことを特徴とするカテーテル組立体(10a)。
    The catheter assembly (10a) according to claim 2,
    A plurality of the frames (54) are provided around the shaft (18), and expand radially when the seal mechanism (50) is expanded.
    A catheter assembly (10a) characterized in that
  5.  請求項4記載のカテーテル組立体(10a)において、
     前記シール機構(50)は、前記複数のフレーム(54)に連結されるとともに前記隔離膜(52)よりも前記シャフト(18)の基端側で前記シャフト(18)に沿って変位自在な連結部材(56)を備える、
     ことを特徴とするカテーテル組立体(10a)。
    The catheter assembly (10a) according to claim 4,
    The seal mechanism (50) is connected to the plurality of frames (54) and is displaceable along the shaft (18) on the proximal end side of the shaft (18) with respect to the isolation film (52). Comprising a member (56),
    A catheter assembly (10a) characterized in that
  6.  請求項5記載のカテーテル組立体(10a)において、
     前記シャフト(18)の外周部には、前記連結部材(56)を解除可能に係止するロック部(60)が設けられる、
     ことを特徴とするカテーテル組立体(10a)。
    Catheter assembly (10a) according to claim 5,
    A lock portion (60) for releasably locking the connecting member (56) is provided on the outer peripheral portion of the shaft (18).
    A catheter assembly (10a) characterized in that
  7.  請求項1~6のいずれか1項に記載のカテーテル組立体(10、10a)において、
     前記シール機構(14、50、70)を押圧する棒状の押圧デバイス(36)を備える、
     ことを特徴とするカテーテル組立体(10、10a)。
    The catheter assembly (10, 10a) according to any one of claims 1 to 6,
    A rod-shaped pressing device (36) for pressing the sealing mechanism (14, 50, 70);
    A catheter assembly (10, 10a) characterized in that.
  8.  請求項7記載のカテーテル組立体(10、10a)において、
     前記シース(16)は、長手方向の途中部位が屈曲しており、
     前記押圧デバイス(36)は、前記シース(16)に沿って曲がる可撓性を有する、
     ことを特徴とするカテーテル組立体(10、10a)。
    The catheter assembly (10, 10a) according to claim 7,
    The sheath (16) is bent in the middle in the longitudinal direction,
    The pressing device (36) has the flexibility to bend along the sheath (16),
    A catheter assembly (10, 10a) characterized in that.
  9.  請求項1~6のいずれか1項に記載のカテーテル組立体(10、10a)において、
     前記ルーメン(18a、81)の内周面は、疎水性を有する、
     ことを特徴とするカテーテル組立体(10、10a)。
    The catheter assembly (10, 10a) according to any one of claims 1 to 6,
    The inner peripheral surface of the lumen (18a, 81) has hydrophobicity,
    A catheter assembly (10, 10a) characterized in that.
  10.  請求項1~6のいずれか1項に記載のカテーテル組立体(10、10a)において、
     前記シール機構(14、50、70)は、透明性を有する、
     ことを特徴とするカテーテル組立体(10、10a)。
    The catheter assembly (10, 10a) according to any one of claims 1 to 6,
    The sealing mechanism (14, 50, 70) has transparency.
    A catheter assembly (10, 10a) characterized in that.
  11.  請求項1~6のいずれか1項に記載のカテーテル組立体(10、10a)において、
     前記シール機構(70)は、前記処置対象部位に接触する側に、環状のシール部材(72)又は多孔質体を有する、
     ことを特徴とするカテーテル組立体(10、10a)。
    The catheter assembly (10, 10a) according to any one of claims 1 to 6,
    The seal mechanism (70) has an annular seal member (72) or a porous body on the side in contact with the treatment target site.
    A catheter assembly (10, 10a) characterized in that.
  12.  請求項1~6のいずれか1項に記載のカテーテル組立体(10、10a)において、
     前記シャフト(80)は、撮像手段を挿入可能な撮像用ルーメン(82)と、光照射手段を挿入可能な照明用ルーメン(83)とを有する、
     ことを特徴とするカテーテル組立体(10、10a)。
    The catheter assembly (10, 10a) according to any one of claims 1 to 6,
    The shaft (80) has an imaging lumen (82) into which the imaging means can be inserted, and an illumination lumen (83) into which the light irradiation means can be inserted.
    A catheter assembly (10, 10a) characterized in that.
  13.  請求項2~6のいずれか1項に記載のカテーテル組立体(10、10a)において、
     前記シャフト(80)は、拡張状態での前記隔離膜(22、52)の略中心を貫通する、
     ことを特徴とするカテーテル組立体(10、10a)。
    The catheter assembly (10, 10a) according to any one of claims 2 to 6,
    The shaft (80) penetrates substantially the center of the isolation membrane (22, 52) in the expanded state;
    A catheter assembly (10, 10a) characterized in that.
PCT/JP2012/081513 2011-12-05 2012-12-05 Catheter assembly WO2013084943A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011265828 2011-12-05
JP2011-265828 2011-12-05

Publications (1)

Publication Number Publication Date
WO2013084943A1 true WO2013084943A1 (en) 2013-06-13

Family

ID=48574301

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/081513 WO2013084943A1 (en) 2011-12-05 2012-12-05 Catheter assembly

Country Status (1)

Country Link
WO (1) WO2013084943A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019155434A1 (en) * 2018-02-09 2019-08-15 Stemmatters, Biotecnologia e Medicina Regenerativa, S.A. Medical device for the delivery of therapeutic formulations and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504857A (en) * 2003-09-09 2007-03-08 ボストン サイエンティフィック リミテッド Lubricant coating for medical devices
JP2008545511A (en) * 2005-06-10 2008-12-18 ボストン サイエンティフィック リミティッド Medical devices having a superhydrophobic surface, a superhydrophilic surface, or both
JP2009529970A (en) * 2006-03-14 2009-08-27 ケーシーアイ ライセンシング インコーポレイテッド A system for applying reduced pressure therapy comprising a manifold having a main flow path and an obstruction prevention member
US20100305549A1 (en) * 2004-04-05 2010-12-02 Bluesky Medical Group Incorporated Reduced pressure wound treatment system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504857A (en) * 2003-09-09 2007-03-08 ボストン サイエンティフィック リミテッド Lubricant coating for medical devices
US20100305549A1 (en) * 2004-04-05 2010-12-02 Bluesky Medical Group Incorporated Reduced pressure wound treatment system
JP2008545511A (en) * 2005-06-10 2008-12-18 ボストン サイエンティフィック リミティッド Medical devices having a superhydrophobic surface, a superhydrophilic surface, or both
JP2009529970A (en) * 2006-03-14 2009-08-27 ケーシーアイ ライセンシング インコーポレイテッド A system for applying reduced pressure therapy comprising a manifold having a main flow path and an obstruction prevention member

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019155434A1 (en) * 2018-02-09 2019-08-15 Stemmatters, Biotecnologia e Medicina Regenerativa, S.A. Medical device for the delivery of therapeutic formulations and methods of use thereof
US20210007779A1 (en) * 2018-02-09 2021-01-14 Stemmatters, Biotecnologia e Medicina Regenerativa, S.A. Medical device for the delivery of therapeutic formulations and methods of use thereof

Similar Documents

Publication Publication Date Title
JP6735787B2 (en) Sheath assembly for inserting a cord-shaped element, in particular a catheter, into the body of a patient
JP5596974B2 (en) Surgical instrument for LVAD transplantation
JP5025269B2 (en) Noninvasive arthroscopy instrument sheath
US8079991B2 (en) Wound suction peg apparatus
US20210038246A1 (en) Method of providing for the minimization of extravasation during arthroscopic surgery
CN103635225A (en) Snap-seal sterile intravascular catheter-dressing system
US10278878B2 (en) Extremity support and irrigation device and method of use
WO2004103210A2 (en) Tunneling device for use with a graft
JP2016185254A (en) Medical equipment
US9731064B2 (en) Multi-port interface device for use with medical fluids
WO2013084943A1 (en) Catheter assembly
WO2013084945A1 (en) Suction catheter
KR20180038052A (en) Device for assisting arterial microvascular anastomosis
US20210379270A1 (en) Suction de-clogger system and method
US11918278B2 (en) Medical delivery systems and methods of using the same
EP2566396B1 (en) Device for sealing perforations and sustaining flow
US20120109110A1 (en) Suction catheter with retractable blade
JP6749311B2 (en) Stent delivery device
KR20210111046A (en) Through type Medical suction device
WO2013081071A1 (en) Device for cell transplantation
JP2015144751A (en) Urethral stenosis therapeutic method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12855614

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12855614

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP